Industry Events Board (pharmaceutics and related)
This board records and monitors material events occurred in United States(US), Europe(EU), and Canada(CA) -- reported by companies in the industries including
pharmaceuticals(n=619), biological products (diagnostic and non diagnostic)(n=196), commercial physical/biological research or service(n=18).
For US, this board tracks status of interventional clinical trials submitted to ClinicalTrials.gov, FDA Human/Animal drugs submission, tentative approval, and marketing status, as well as CBER approved biological products. For EU, it tracks Europe Medicines Agency (EMA) regulated Human/Animal drugs marketing, and summary of opinion. For CA, it tracks Human/Animal drugs marketing and approval regulated by Canadian Food Inspection Agency (CFIA) and Health Canada.
This board provides powerful sorting strategies to help investors find, for example, companies with the most recent drug marketing in specific country/area, or with most approvals in specific year, or with research focus in specific disease condition(s). The information are presented together with Simple Moving Average (SMA) thumbnail chart and links to insider tradings and institutional holdings. For each company, there is also a standalone webpage describing the details of clinical trials and a list of drugs that are approved/marketed.
Sort Results
by US clinical trial count (largest first):
| Year: | Recruitment Status: | Phase: |
by US clinical trial focus of disease condition(s):
| Status(es): | Phase(s): |
Show Other Sort/Display Options
by US FDA submission count (largest first):
| Year: | Type: |
by US FDA submission time (latest first):
| Type(s): |
by US drug marketing count (largest first):
| Year: | Scope: | Status: |
by EU drug marketing count (largest first):
| Year: | Scope: | Status: |
by CA drug marketing count (largest first):
| Year: | Scope: | Status: |
by US drug marketing time (latest first):
| Scope(s): | Status(es): |
by EU drug marketing time (latest first):
| Scope(s): | Status(es): |
by CA drug marketing time (latest first):
| Scope(s): | Status(es): |
Display Options
| Force Include Symbol (pharmaceutics and related company): |
||
| Historical Years: | Clinical Trial Status(es): | Clinical Trial Phase(s): |
| Thumbnail SMA: | SMA Years: | |
| Max Records Number: |
Instructions
Only one sorting strategy will be applied for each query. When no checkbox is selected, default is "by US clinical trial count".
Count related sort: (e.g. by US clinical trial count; by US FDA submission count) orders results descendingly by the number of matched records.
Time related sort: (e.g. by US FDA submission time; by US drug marketing time) orders results by the most recent update time. For each option, when multiple categories are selected (e.g. both Phase 1 and Phase 2 are selected), the sorting will be based on the most recent update in either category, whichever contains the latest update.
US clinical trial focus of disease condition(s): select one or more disease conditions from the left box and move to the right box. The search results will be sorted based on relevence to condition(s) appearred in the right box.
Clinical trial recruitment statuses: simplified to 4 major categories according to the original statuses appearred in interventional studies on ClinicalTrails.gov.
Ongoing: Active, not recruiting; Enrolling by invitation; Recruiting; Not yet recruiting
Finished: Completed
Abnormal: Unknown status; Suspended
Aborted: Terminated; Withdrawn
Clinical trial phases: simplified to 5 major categories according to the original phases used by ClinicalTrails.gov
Phase 1: Early Phase 1; Phase 1
Phase 2: Phase 1|Phase 2; Phase 2
Phase 3: Phase 2|Phase 3; Phase 3
Phase 4: Phase 4
Phase NA: All other scenarios
US FDA submission types
Type 1: Type 1 - New Molecular Entity; Type 1 - New Molecular Entity and Type 4 - New Combination
Type 2: Type 2 - New Active Ingredient; Type 2 - New Active Ingredient and Type 3 - New Dosage Form; Type 2 New Active Ingredient and Type 4 New Combination
Type 3: Type 3 - New Dosage Form; Type 3 - New Dosage Form and Type 4 - New Combination
Others: All other scenarios
US, EU, CA drug marketing status
US drugs scope "Bioproduct" contains biological products that are approved by the Center for Biologics Evaluation and Research (CBER).
US drugs status "Tentative Approval": granted by the FDA if an abbreviated new drug application(ANDA) meets the substantive requirements for approval but cannot obtain final approval due to unexpired patents or exclusivities.
Europe drugs status "positive": summary of opinion published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. This summary is replaced by a full European public assessment reports once the European Commission has decided - taking the EMA opinion into consideration - whether to grant the marketing authorisation.
Drug products with same active ingredient but different forms or dosage strengthes are counted only once
Force include symbols
Add trading symbols for any pharmaceutics related company. The corresponding records will be forced to be displayed at the begining of the retrieved results. The force included records have lightgreen background.
Result Table Explained
Clinical trail count: the number of clinical trials started in corresponding year.
FDA submissions: the number of "ORIGINAL" (i.e. Supplementary not considered) FDA submissions in corresponding year.
⬤ latest update ≤ 7 days
⬤ latest update ≤ 30 days
⬤ latest update ≤ 90 days
Data last updated 2024-07-26 23:25:06 -0500 US CDT
US Clinical Trials and FDA Submissions
| Symbol | SMA (50w/20w/10w/5w / 50d/20d/10d/5d) | Research Focus | Year | Clinical Trials Count | US FDA submissions | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ongoing | |||||||||||
| Phase 1 | Phase 2 | Phase 3 | Phase 4 | Type 1 | Type 2 | Type 3 | Others | ||||
|
AZN
(AstraZeneca PLC) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(14) Carcinoma, Non-Small-Cell Lung(8) Breast Neoplasms(6) Liver Diseases(3) Crohn Disease(3) Dyslipidemias(3) Lung Neoplasms(3) COVID-19(2) Neurofibroma, Plexiform(2) Neurofibroma(2) Neurofibromatosis 1(2) (skip...) Phase 1:Finished: Diabetes Mellitus, Type 2(58) Neoplasms(57) Diabetes Mellitus(25) Pulmonary Disease, Chronic Obstructive(24) Lung Diseases, Obstructive(23) Carcinoma, Non-Small-Cell Lung(15) Arthritis(14) Asthma(13) Arthritis, Rheumatoid(13) Alzheimer Disease(13) Breast Neoplasms(12) (skip...) Phase 1:Aborted: Neoplasms(12) Diabetes Mellitus, Type 2(4) Pulmonary Disease, Chronic Obstructive(4) Leukemia, Myeloid, Acute(4) Leukemia, Myeloid(4) Lymphoma(4) Lung Diseases, Obstructive(3) Leukemia(3) Fatty Liver(2) Hematologic Neoplasms(2) Heart Failure(2) (skip...) Phase 2:Ongoing: Carcinoma, Non-Small-Cell Lung(17) Lung Neoplasms(15) Neoplasms(11) Lymphoma(6) Breast Neoplasms(6) Stomach Neoplasms(6) Adenocarcinoma(4) Carcinoma(4) Carcinoma, Hepatocellular(3) Fibrosis(3) Hypertension(3) (skip...) Phase 2:Finished: Lung Diseases, Obstructive(32) Pulmonary Disease, Chronic Obstructive(31) Diabetes Mellitus(29) Breast Neoplasms(28) Diabetes Mellitus, Type 2(28) Lung Diseases(27) Asthma(25) Carcinoma, Non-Small-Cell Lung(14) Prostatic Neoplasms(14) Lung Neoplasms(13) (9) (skip...) Phase 2:Abnormal: Kidney Neoplasms(1) Carcinoma, Renal Cell(1) Carcinoma(1) Phase 2:Aborted: Arthritis, Rheumatoid(5) Arthritis(5) Carcinoma, Non-Small-Cell Lung(5) Lung Neoplasms(5) Pulmonary Disease, Chronic Obstructive(3) Lung Diseases(3) Depression(3) Depressive Disorder(3) Diabetes Mellitus, Type 2(3) Colorectal Neoplasms(3) Asthma(2) (skip...) Phase 3:Ongoing: Carcinoma, Non-Small-Cell Lung(28) Lung Neoplasms(24) Breast Neoplasms(19) Asthma(13) Carcinoma(13) Pulmonary Disease, Chronic Obstructive(8) Lung Diseases, Obstructive(8) Lung Diseases(8) Carcinoma, Hepatocellular(6) Biliary Tract Neoplasms(5) Prostatic Neoplasms(5) (skip...) Phase 3:Finished: Asthma(97) Diabetes Mellitus, Type 2(97) Diabetes Mellitus(88) Pulmonary Disease, Chronic Obstructive(45) Lung Diseases, Obstructive(45) Lung Diseases(38) Hypercholesterolemia(25) Depressive Disorder(23) Depression(23) Breast Neoplasms(18) Disease(18) (skip...) Phase 3:Abnormal: Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Phase 3:Aborted: Diabetes Mellitus, Type 2(14) Schizophrenia(4) Diabetes Mellitus(4) Hyperkalemia(3) Alzheimer Disease(3) Asthma(3) Renal Insufficiency, Chronic(2) Crohn Disease(2) Anemia, Sickle Cell(2) Dementia(2) Breast Neoplasms(2) (skip...) Phase 4:Ongoing: Asthma(4) Hyperkalemia(2) Breast Neoplasms(1) Diabetes Mellitus, Type 2(1) Pulmonary Eosinophilia(1) Prostatic Neoplasms(1) Renal Insufficiency, Chronic(1) Kidney Diseases(1) Heart Failure(1) Phase 4:Finished: Diabetes Mellitus, Type 2(23) Diabetes Mellitus(22) Gastroesophageal Reflux(21) Asthma(17) Pulmonary Disease, Chronic Obstructive(15) Lung Diseases, Obstructive(13) Lung Diseases(11) Schizophrenia(9) Carcinoma, Non-Small-Cell Lung(7) Esophagitis, Peptic(7) Heartburn(6) (skip...) Phase 4:Aborted: Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Hypercholesterolemia(3) Bipolar Disorder(3) Prostatic Neoplasms(2) COVID-19(1) Hyperkalemia(1) Pneumonia(1) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases, Obstructive(1) Lung Diseases(1) (skip...) Phase Not Applicable:Ongoing: Asthma(1) Phase Not Applicable:Finished: Asthma(4) Hyperlipidemias(1) Dyslipidemias(1) Hypertension(1) Infarction(1) Myocardial Infarction(1) Carcinoma, Non-Small-Cell Lung(1) Lung Neoplasms(1) Cardiovascular Diseases(1) Peripheral Vascular Diseases(1) Peripheral Arterial Disease(1) (skip...) |
ALL | 59 | 83 | 145 | 10 | 29 | 3 | 18 | 30 |
| 2024 | 12 ⬤ | 10 ⬤ | 12 ⬤ | 3 ⬤ | - | - | - | - | |||
| 2023 | 12 ⬤ | 23 ⬤ | 34 ⬤ | - | 2 | - | - | 2 | |||
| 2022 | 8 ⬤ | 13 ⬤ | 22 ⬤ | 4 ⬤ | 1 | - | 1 | 1 | |||
|
MRK
(Merck & Company Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(8) Alzheimer Disease(3) Carcinoma, Renal Cell(3) Carcinoma(3) Liver Diseases(2) Prostatic Neoplasms(2) Renal Insufficiency(2) Hematologic Neoplasms(2) Cognitive Dysfunction(2) Neoplasm Metastasis(1) Malaria(1) (skip...) Phase 1:Finished: Diabetes Mellitus, Type 2(39) Hepatitis C(32) Diabetes Mellitus(28) Neoplasms(27) Hepatitis(26) Renal Insufficiency(25) Hypertension(22) Hepatitis A(18) HIV Infections(15) Liver Failure(12) Hepatic Insufficiency(12) (skip...) Phase 1:Aborted: Neoplasms(13) Leukemia, Myeloid(6) Leukemia(6) Hepatitis(5) Hepatitis C, Chronic(5) Hepatitis C(5) Hepatitis A(4) Renal Insufficiency(4) Precursor Cell Lymphoblastic Leukemia-Lymphoma(4) Leukemia, Myeloid, Acute(3) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(3) (skip...) Phase 2:Ongoing: Carcinoma(15) Neoplasms(11) Lymphoma(10) Carcinoma, Renal Cell(8) Hematologic Neoplasms(5) Carcinoma, Non-Small-Cell Lung(5) Melanoma(5) Esophageal Neoplasms(4) Hodgkin Disease(4) Lymphoma, B-Cell(4) Lymphoma, Large B-Cell, Diffuse(3) (skip...) Phase 2:Finished: Hepatitis(31) Hepatitis C(31) Hepatitis A(29) Hepatitis C, Chronic(24) Infections(18) Carcinoma(16) Carcinoma, Non-Small-Cell Lung(14) Diabetes Mellitus, Type 2(13) Breast Neoplasms(13) HIV Infections(13) Communicable Diseases(12) (skip...) Phase 2:Abnormal: HIV Infections(4) Phase 2:Aborted: Carcinoma, Non-Small-Cell Lung(9) Diabetes Mellitus, Type 2(8) Neoplasms(8) Diabetes Mellitus(7) (6) Hepatitis C(5) Hepatitis A(5) Lung Diseases(5) Hepatitis(4) Syndrome(4) Infections(4) (skip...) Phase 3:Ongoing: Carcinoma, Non-Small-Cell Lung(22) Carcinoma(21) Lung Neoplasms(21) Carcinoma, Squamous Cell(7) Carcinoma, Renal Cell(7) Papillomavirus Infections(6) Adenocarcinoma(6) Melanoma(6) Hypertension(5) Familial Primary Pulmonary Hypertension(5) Pulmonary Arterial Hypertension(5) (skip...) Phase 3:Finished: Diabetes Mellitus, Type 2(72) Diabetes Mellitus(71) Hepatitis(46) Hepatitis A(45) Hepatitis C(36) Infections(31) Hepatitis C, Chronic(30) Pneumococcal Infections(29) Communicable Diseases(25) Herpes Zoster(22) Papillomavirus Infections(20) (skip...) Phase 3:Abnormal: Papillomavirus Infections(1) Phase 3:Aborted: Diabetes Mellitus, Type 2(13) Hepatitis(10) Hepatitis A(10) Hepatitis C(9) Hepatitis C, Chronic(7) Dyslipidemias(6) Diabetes Mellitus(6) Hypercholesterolemia(5) Hepatitis, Chronic(3) Herpes Zoster(3) Osteoporosis(3) (skip...) Phase 4:Ongoing: Squamous Cell Carcinoma of Head and Neck(1) Carcinoma, Squamous Cell(1) Carcinoma(1) Melanoma(1) Carcinoma, Non-Small-Cell Lung(1) Phase 4:Finished: Sclerosis(10) Multiple Sclerosis(10) Diabetes Mellitus, Type 2(7) Diabetes Mellitus(7) Hepatitis(7) Infections(7) Hypertension(6) Hepatitis A(6) Vomiting(6) Nausea(6) Spondylitis(5) (skip...) Phase 4:Aborted: Hepatitis(8) Hepatitis A(8) Hepatitis C(7) Hepatitis C, Chronic(6) Infertility(4) Psoriasis(3) Diabetes Mellitus, Type 2(2) Diabetes Mellitus(2) Spondylitis, Ankylosing(2) Spondylitis(2) Breast Neoplasms(2) (skip...) Phase Not Applicable:Finished: HIV Infections(6) Osteoporosis(4) Diabetes Mellitus, Type 2(2) Diabetes Mellitus(2) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases(1) Glucose Intolerance(1) Hyperglycemia(1) Insulin Resistance(1) Hypertension(1) Asthma(1) (skip...) Phase Not Applicable:Aborted: Multiple Myeloma(1) |
ALL | 34 | 81 | 138 | 2 | 41 | 6 | 33 | 26 |
| 2024 | 7 ⬤ | 10 ⬤ | 16 ⬤ | - | - | - | - | - | |||
| 2023 | 8 ⬤ | 10 ⬤ | 21 ⬤ | - | - | - | - | - | |||
| 2022 | 6 ⬤ | 12 ⬤ | 17 ⬤ | - | - | - | - | - | |||
|
NVS
(Novartis AG) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Carcinoma, Non-Small-Cell Lung(5) Colorectal Neoplasms(5) Glioblastoma(4) Leukemia(4) Carcinoma(4) Melanoma(4) Lymphoma, Non-Hodgkin(3) Lymphoma(3) Neoplasms, Plasma Cell(3) Multiple Myeloma(3) Leukemia, Myeloid, Acute(3) (skip...) Phase 1:Finished: Neoplasms(51) Breast Neoplasms(26) Liver Diseases(23) Renal Insufficiency(17) Lymphoma(14) Multiple Myeloma(11) Leukemia(11) Neoplasms, Plasma Cell(10) Leukemia, Myeloid(10) Carcinoma, Non-Small-Cell Lung(9) Lung Neoplasms(9) (skip...) Phase 1:Aborted: Neoplasms(11) Carcinoma, Non-Small-Cell Lung(7) Leukemia(7) Leukemia, Lymphoid(5) Lung Neoplasms(4) Lymphoma(4) Colorectal Neoplasms(4) Carcinoma(4) Melanoma(3) Renal Insufficiency(3) Neoplasm Metastasis(3) (skip...) Phase 2:Ongoing: Leukemia(11) Leukemia, Myeloid(9) Breast Neoplasms(7) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(7) Prostatic Neoplasms(6) Osteoarthritis(6) Osteoarthritis, Knee(5) Lung Neoplasms(5) Carcinoma, Non-Small-Cell Lung(5) Syndrome(5) Myelodysplastic Syndromes(4) (skip...) Phase 2:Finished: Influenza, Human(42) Asthma(33) Breast Neoplasms(28) Leukemia(28) Hypertension(25) Syndrome(23) Meningococcal Infections(22) Carcinoma(21) Pulmonary Disease, Chronic Obstructive(18) Neoplasms(18) Leukemia, Myeloid(17) (skip...) Phase 2:Aborted: Asthma(11) Breast Neoplasms(11) Carcinoma(10) Leukemia(10) Carcinoma, Non-Small-Cell Lung(9) Syndrome(9) Lung Neoplasms(8) Neoplasms(8) Leukemia, Myeloid(7) Hypertension(6) Myelodysplastic Syndromes(5) (skip...) Phase 3:Ongoing: Sclerosis(9) Syndrome(8) Multiple Sclerosis(8) Hypercholesterolemia(6) Leukemia(6) Cardiovascular Diseases(5) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(5) Leukemia, Myeloid(5) Urticaria(4) Giant Cell Arteritis(4) Polymyalgia Rheumatica(4) (skip...) Phase 3:Finished: Hypertension(105) Diabetes Mellitus, Type 2(65) Diabetes Mellitus(62) Pulmonary Disease, Chronic Obstructive(55) Lung Diseases, Obstructive(55) Influenza, Human(50) Lung Diseases(45) Meningococcal Infections(35) Breast Neoplasms(35) Psoriasis(30) Meningitis(28) (skip...) Phase 3:Abnormal: Breast Neoplasms(1) Phase 3:Aborted: Carcinoma, Non-Small-Cell Lung(7) Leukemia(7) Uveitis(6) Breast Neoplasms(6) Syndrome(6) Pulmonary Disease, Chronic Obstructive(5) Macular Edema(5) Sclerosis(5) Multiple Sclerosis(5) Lung Neoplasms(5) Hepatitis(5) (skip...) Phase 4:Ongoing: Sclerosis(7) Multiple Sclerosis(6) Hypercholesterolemia(3) Leukemia, Myeloid(3) Atherosclerosis(2) Cardiovascular Diseases(2) Breast Neoplasms(2) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(2) Leukemia(2) Multiple Sclerosis, Relapsing-Remitting(2) Carcinoma, Non-Small-Cell Lung(2) (skip...) Phase 4:Finished: Hypertension(63) Diabetes Mellitus(27) Diabetes Mellitus, Type 2(25) Sclerosis(20) Multiple Sclerosis(19) Pulmonary Disease, Chronic Obstructive(18) Macular Degeneration(17) Lung Diseases, Obstructive(16) Neoplasm Metastasis(16) Alzheimer Disease(14) Prostatic Neoplasms(13) (skip...) Phase 4:Aborted: Sclerosis(6) Multiple Sclerosis(6) Fibrosis(4) Hepatitis(4) Diabetes Mellitus(4) Hypertension(4) Breast Neoplasms(4) Multiple Sclerosis, Relapsing-Remitting(3) Asthma(3) Cystic Fibrosis(3) Infections(3) (skip...) Phase Not Applicable:Ongoing: Psoriasis(1) Arthritis, Psoriatic(1) Arthritis(1) Phase Not Applicable:Finished: Refractive Errors(4) Presbyopia(2) Heart Failure(2) Psoriasis(1) Arthritis, Psoriatic(1) Arthritis(1) Cardiovascular Diseases(1) Hyperopia(1) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases, Obstructive(1) Lung Diseases(1) (skip...) Phase Not Applicable:Aborted: Astigmatism(1) Cataract(1) |
ALL | 42 | 86 | 103 | 31 | 73 | 5 | 45 | 56 |
| 2024 | 4 ⬤ | 3 ⬤ | 5 ⬤ | 7 ⬤ | - | - | - | - | |||
| 2023 | 5 ⬤ | 12 ⬤ | 21 ⬤ | 2 ⬤ | - | - | 1 | 2 | |||
| 2022 | 8 ⬤ | 18 ⬤ | 20 ⬤ | 4 ⬤ | 1 | 1 | - | 1 | |||
|
ABBV
(AbbVie Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(11) Carcinoma, Non-Small-Cell Lung(5) Neoplasms, Plasma Cell(4) Multiple Myeloma(4) Leukemia, Lymphocytic, Chronic, B-Cell(4) Leukemia, Lymphoid(4) Leukemia(3) Lymphoma(3) Hematologic Neoplasms(3) Anxiety Disorders(2) Lymphoma, B-Cell(2) (skip...) Phase 1:Finished: Neoplasms(26) Leukemia(8) Lymphoma(7) Lung Neoplasms(6) Lymphoma, Non-Hodgkin(5) Leukemia, Lymphocytic, Chronic, B-Cell(5) Ovarian Neoplasms(5) Leukemia, Myeloid, Acute(4) Parkinson Disease(4) Leukemia, Lymphoid(4) Arthritis, Rheumatoid(4) (skip...) Phase 1:Aborted: Leukemia, Myeloid, Acute(6) Leukemia, Myeloid(6) Leukemia(5) Neoplasms, Plasma Cell(4) Multiple Myeloma(4) Lymphoma(4) Lymphoma, Non-Hodgkin(4) Colorectal Neoplasms(3) Carcinoma, Non-Small-Cell Lung(2) Lymphoma, B-Cell(2) Breast Neoplasms(2) (skip...) Phase 2:Ongoing: Leukemia, Lymphocytic, Chronic, B-Cell(3) Leukemia, Lymphoid(3) Leukemia(3) Lymphoma(3) Colorectal Neoplasms(2) (2) Colitis, Ulcerative(2) Colitis(2) Alzheimer Disease(2) Choroidal Effusions(2) Wet Macular Degeneration(2) (skip...) Phase 2:Finished: Hepatitis C(21) Hepatitis C, Chronic(19) Hepatitis A(18) Hepatitis(17) Arthritis(15) Arthritis, Rheumatoid(12) Hepatitis, Chronic(10) Infections(10) Leukemia(8) Lung Neoplasms(8) Communicable Diseases(7) (skip...) Phase 2:Aborted: Arthritis(3) Alzheimer Disease(3) Arthritis, Rheumatoid(2) Neoplasms, Plasma Cell(2) Multiple Myeloma(2) Supranuclear Palsy, Progressive(2) Lung Neoplasms(2) Disease(2) Internal Hernia(1) Hernia, Abdominal(1) Hernia, Ventral(1) (skip...) Phase 3:Ongoing: Migraine Disorders(12) Arthritis(8) Eczema(7) Dermatitis(7) Dermatitis, Atopic(7) Crohn Disease(6) Leukemia(6) Arthritis, Psoriatic(5) Leukemia, Myeloid, Acute(5) Leukemia, Myeloid(5) (5) (skip...) Phase 3:Finished: Hepatitis C(52) Hepatitis A(52) Hepatitis(47) Hepatitis C, Chronic(45) Infections(31) Psoriasis(25) Hepatitis, Chronic(22) Communicable Diseases(19) Parkinson Disease(12) Arthritis(11) Virus Diseases(10) (skip...) Phase 3:Aborted: Small Cell Lung Carcinoma(2) Lung Neoplasms(2) Hepatitis C, Chronic(2) Hepatitis C(2) Hepatitis A(2) Kidney Diseases(2) Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Schizophrenia(1) Glioblastoma(1) (skip...) Phase 4:Ongoing: Psoriasis(2) Inflammatory Bowel Diseases(1) Intestinal Diseases(1) Facies(1) Glaucoma, Open-Angle(1) Glaucoma(1) Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Panuveitis(1) Uveitis(1) (skip...) Phase 4:Finished: Arthritis(5) Arthritis, Rheumatoid(4) Psoriasis(3) Fibrosis(2) Exocrine Pancreatic Insufficiency(2) Cystic Fibrosis(2) Hypogonadism(2) HIV Infections(2) Facies(1) Migraine Disorders(1) Pancreatitis, Chronic(1) (skip...) Phase 4:Aborted: Exocrine Pancreatic Insufficiency(2) Pancreatitis, Chronic(1) Pancreatitis(1) Cystic Fibrosis(1) Pancreatic Neoplasms(1) Spondylarthritis(1) |
ALL | 36 | 32 | 94 | 8 | 42 | 6 | 48 | 41 |
| 2024 | 6 ⬤ | 1 ⬤ | 13 ⬤ | 3 ⬤ | - | - | - | - | |||
| 2023 | 8 ⬤ | 9 ⬤ | 23 ⬤ | 2 ⬤ | - | - | - | - | |||
| 2022 | 5 ⬤ | 3 ⬤ | 11 ⬤ | 2 | - | - | 1 | - | |||
|
LLY
(Lilly Eli & Company) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(8) Overweight(7) Obesity(6) Breast Neoplasms(6) Carcinoma, Non-Small-Cell Lung(5) Diabetes Mellitus(4) Diabetes Mellitus, Type 2(3) Urinary Bladder Neoplasms(3) Triple Negative Breast Neoplasms(2) Recurrence(2) Prostatic Neoplasms(2) (skip...) Phase 1:Finished: Diabetes Mellitus(68) Diabetes Mellitus, Type 2(59) Neoplasms(49) Diabetes Mellitus, Type 1(26) Neoplasm Metastasis(24) Depressive Disorder, Major(17) Depressive Disorder(17) Alzheimer Disease(12) Renal Insufficiency(10) Carcinoma, Non-Small-Cell Lung(10) Overweight(8) (skip...) Phase 1:Aborted: Diabetes Mellitus(5) Neoplasms(5) Diabetes Mellitus, Type 1(3) Diabetes Mellitus, Type 2(3) Triple Negative Breast Neoplasms(2) Carcinoma, Non-Small-Cell Lung(2) Carcinoma, Renal Cell(2) Neoplasm Metastasis(2) Carcinoma(2) Leukemia(2) Dermatitis(1) (skip...) Phase 2:Ongoing: Obesity(8) Overweight(6) Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Neoplasms(3) Neuralgia(2) Psoriasis(2) Renal Insufficiency, Chronic(2) Kidney Diseases(2) Arthritis, Rheumatoid(2) Arthritis(2) (skip...) Phase 2:Finished: Carcinoma, Non-Small-Cell Lung(65) Lung Neoplasms(62) Breast Neoplasms(38) Diabetes Mellitus(23) Neoplasms(20) Diabetes Mellitus, Type 2(19) Carcinoma(19) Colorectal Neoplasms(15) Alzheimer Disease(10) Ovarian Neoplasms(10) Arthritis, Rheumatoid(9) (skip...) Phase 2:Aborted: Lung Neoplasms(13) Carcinoma, Non-Small-Cell Lung(8) Diabetes Mellitus, Type 2(5) Diabetes Mellitus(5) Small Cell Lung Carcinoma(4) Carcinoma(3) Arthritis, Rheumatoid(2) Arthritis(2) Alzheimer Disease(2) Headache(2) Migraine Disorders(2) (skip...) Phase 3:Ongoing: Diabetes Mellitus, Type 2(16) Diabetes Mellitus(16) Obesity(16) Overweight(11) Eczema(8) Dermatitis(8) Dermatitis, Atopic(8) Breast Neoplasms(8) (7) Colitis, Ulcerative(6) Colitis(6) (skip...) Phase 3:Finished: Diabetes Mellitus(83) Diabetes Mellitus, Type 2(61) Depressive Disorder(24) Attention Deficit Disorder with Hyperactivity(23) Hyperkinesis(22) Diabetes Mellitus, Type 1(21) Depressive Disorder, Major(21) Lung Neoplasms(19) Osteoporosis(18) Carcinoma, Non-Small-Cell Lung(18) Depression(17) (skip...) Phase 3:Aborted: Lupus Erythematosus, Systemic(4) Arthritis, Rheumatoid(4) Arthritis(4) Alzheimer Disease(3) Hypercholesterolemia(2) Schizophrenia(2) (1) Colitis, Ulcerative(1) Colitis(1) Psoriasis(1) Eczema(1) (skip...) Phase 4:Ongoing: Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Arthritis(3) Arthritis, Rheumatoid(2) Psoriasis(1) Arthritis, Psoriatic(1) Phase 4:Finished: Diabetes Mellitus, Type 2(25) Diabetes Mellitus(21) Depressive Disorder(21) Attention Deficit Disorder with Hyperactivity(19) Schizophrenia(16) Depression(16) Osteoporosis(16) Hyperkinesis(14) Depressive Disorder, Major(13) Erectile Dysfunction(12) Disease(11) (skip...) Phase 4:Aborted: Breast Neoplasms(2) Diabetes Mellitus, Type 2(2) Diabetes Mellitus(2) Attention Deficit Disorder with Hyperactivity(2) Hyperkinesis(2) Myofascial Pain Syndromes(1) Fibromyalgia(1) Bipolar Disorder(1) Marijuana Abuse(1) Disease(1) Phase Not Applicable:Ongoing: Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Phase Not Applicable:Finished: Diabetes Mellitus(5) Diabetes Mellitus, Type 1(4) Diabetes Mellitus, Type 2(1) Migraine Disorders(1) |
ALL | 55 | 33 | 81 | 6 | 37 | 4 | 17 | 48 |
| 2024 | 17 ⬤ | 4 ⬤ | 10 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2023 | 19 ⬤ | 12 ⬤ | 23 ⬤ | 1 | 1 | - | - | 1 | |||
| 2022 | 7 ⬤ | 7 ⬤ | 12 ⬤ | 2 ⬤ | 1 | - | - | - | |||
|
PFE
(Pfizer Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Multiple Myeloma(6) Neoplasms, Plasma Cell(5) Breast Neoplasms(5) Colorectal Neoplasms(4) Lymphoma(4) Neoplasms(4) Carcinoma, Non-Small-Cell Lung(3) Carcinoma(3) Melanoma(3) Renal Insufficiency(2) COVID-19(2) (skip...) Phase 1:Finished: Alzheimer Disease(38) Diabetes Mellitus, Type 2(37) Neoplasms(33) Diabetes Mellitus(26) Arthritis, Rheumatoid(18) Arthritis(18) Liver Diseases(17) Renal Insufficiency(16) Overweight(14) Schizophrenia(11) Carcinoma, Non-Small-Cell Lung(10) (skip...) Phase 1:Aborted: Neoplasms(22) Breast Neoplasms(10) Carcinoma, Non-Small-Cell Lung(6) Lung Neoplasms(5) Diabetes Mellitus, Type 2(5) Schizophrenia(4) Carcinoma, Renal Cell(3) Carcinoma(3) Hypertension(3) Hypercholesterolemia(3) Colorectal Neoplasms(3) (skip...) Phase 2:Ongoing: Breast Neoplasms(10) Neoplasms, Plasma Cell(4) Multiple Myeloma(4) Carcinoma, Non-Small-Cell Lung(3) Influenza, Human(2) Gram-Negative Bacterial Infections(2) Bacterial Infections(2) Communicable Diseases(2) Infections(2) Lymphoma, Large B-Cell, Diffuse(2) Lymphoma, B-Cell(2) (skip...) Phase 2:Finished: Arthritis(25) Carcinoma, Non-Small-Cell Lung(25) Arthritis, Rheumatoid(24) Breast Neoplasms(21) Lung Neoplasms(18) Alzheimer Disease(16) Psoriasis(14) Carcinoma(14) Diabetes Mellitus, Type 2(13) Diabetes Mellitus(13) Carcinoma, Renal Cell(13) (skip...) Phase 2:Aborted: Breast Neoplasms(15) Carcinoma, Non-Small-Cell Lung(9) Lung Neoplasms(9) Diabetes Mellitus(7) Neoplasms(7) Alzheimer Disease(6) Diabetes Mellitus, Type 2(6) Infections(5) Schizophrenia(5) Osteoarthritis(5) Neuralgia(5) (skip...) Phase 3:Ongoing: Anemia, Sickle Cell(8) Migraine Disorders(7) Hemophilia A(7) Hemophilia B(6) Neoplasms, Plasma Cell(4) Multiple Myeloma(4) Breast Neoplasms(4) Vitiligo(3) (3) Prostatic Neoplasms(3) Lyme Disease(2) (skip...) Phase 3:Finished: Depression(31) Infections(30) Pneumococcal Infections(29) Arthritis(29) Depressive Disorder(29) Communicable Diseases(26) Depressive Disorder, Major(25) Arthritis, Rheumatoid(19) Disease(16) (16) Pneumonia(14) (skip...) Phase 3:Aborted: Osteoarthritis(9) Infections(9) Alzheimer Disease(8) Hypertension(7) Diabetes Mellitus(7) Communicable Diseases(7) Hypertension, Pulmonary(5) Anxiety Disorders(5) Carcinoma(5) Carcinoma, Non-Small-Cell Lung(5) Hyperlipidemias(5) (skip...) Phase 4:Ongoing: Migraine Disorders(4) Carcinoma, Non-Small-Cell Lung(2) Neoplasms, Plasma Cell(1) Multiple Myeloma(1) Leukemia, Lymphoid(1) Precursor Cell Lymphoblastic Leukemia-Lymphoma(1) Leukemia(1) Invasive Fungal Infections(1) Mycoses(1) Myocarditis(1) Photophobia(1) (skip...) Phase 4:Finished: Arthritis(18) Arthritis, Rheumatoid(14) Infections(12) Communicable Diseases(10) Psoriasis(9) Hemophilia A(9) Renal Insufficiency(9) Spondylitis, Ankylosing(8) Spondylitis(8) Depressive Disorder(8) Depression(8) (skip...) Phase 4:Aborted: Arthritis(4) Hemophilia A(4) Attention Deficit Disorder with Hyperactivity(3) Hyperkinesis(3) Arthritis, Rheumatoid(3) Wounds and Injuries(3) Brain Injuries(3) (2) Endocrine System Diseases(2) Dwarfism, Pituitary(2) Venous Thromboembolism(2) (skip...) Phase Not Applicable:Finished: Meningitis(11) Meningococcal Infections(11) Meningitis, Cryptococcal(10) Infections(8) HIV Infections(7) Communicable Diseases(6) Acquired Immunodeficiency Syndrome(6) Mycobacterium avium-intracellulare Infection(4) Mycobacterium Infections(4) Candidiasis(4) Immunologic Deficiency Syndromes(3) (skip...) Phase Not Applicable:Aborted: Disease Progression(1) Amyloidosis(1) Cardiomyopathies(1) Heart Failure(1) Alzheimer Disease(1) Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Cystitis, Interstitial(1) Cystitis(1) |
ALL | 53 | 46 | 61 | 12 | 73 | 7 | 52 | 63 |
| 2024 | 16 ⬤ | 4 ⬤ | 1 ⬤ | - | - | - | - | - | |||
| 2023 | 16 ⬤ | 10 ⬤ | 11 ⬤ | 2 ⬤ | 6 | - | - | - | |||
| 2022 | 9 ⬤ | 11 ⬤ | 16 ⬤ | 7 ⬤ | 1 | - | - | - | |||
|
SNY
(Sanofi SA) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(2) Respiratory Syncytial Virus Infections(1) Communicable Diseases(1) Infections(1) Hemophilia A(1) Osteogenesis Imperfecta(1) Anemia, Hemolytic(1) Anemia, Hemolytic, Autoimmune(1) Breast Neoplasms(1) Phase 1:Finished: Neoplasms(36) Diabetes Mellitus(27) Diabetes Mellitus, Type 1(19) Diabetes Mellitus, Type 2(17) Hypercholesterolemia(9) Leukemia(9) Multiple Sclerosis(8) Influenza, Human(8) Arthritis, Rheumatoid(7) Arthritis(7) Neoplasms, Plasma Cell(7) (skip...) Phase 1:Aborted: Neoplasms(4) Neoplasm Metastasis(2) Lung Neoplasms(2) Leukemia, Myeloid, Acute(2) Leukemia, Myeloid(2) Leukemia(2) Smallpox(2) Coronavirus Infections(1) Herpes Genitalis(1) Herpes Simplex(1) Neoplasms, Plasma Cell(1) (skip...) Phase 2:Ongoing: Neoplasms, Plasma Cell(5) Multiple Myeloma(5) Dermatitis(4) Dermatitis, Atopic(4) (4) Lung Neoplasms(4) Hidradenitis(3) Hidradenitis Suppurativa(3) Respiratory Syncytial Virus Infections(3) Asthma(3) Carcinoma, Non-Small-Cell Lung(3) (skip...) Phase 2:Finished: Influenza, Human(40) Breast Neoplasms(19) (18) Severe Dengue(17) Hemorrhagic Fevers, Viral(17) Dengue(17) Meningococcal Infections(17) Meningitis(16) Orthomyxoviridae Infections(15) Lung Neoplasms(15) Carcinoma, Non-Small-Cell Lung(14) (skip...) Phase 2:Abnormal: Melanoma(2) Phase 2:Aborted: Leukemia(6) Lymphoma(6) Breast Neoplasms(5) Syndrome(5) Sclerosis(5) Malaria(4) Leukemia, Myeloid, Acute(4) Carcinoma, Non-Small-Cell Lung(4) Lymphoma, Non-Hodgkin(4) Leukemia, Lymphoid(3) Precursor Cell Lymphoblastic Leukemia-Lymphoma(3) (skip...) Phase 3:Ongoing: Sclerosis(9) Multiple Sclerosis(9) Dermatitis(5) Dermatitis, Atopic(5) Pulmonary Disease, Chronic Obstructive(4) Lung Diseases, Obstructive(4) Lung Diseases(4) Multiple Sclerosis, Chronic Progressive(4) Hemophilia A(4) Neoplasms, Plasma Cell(4) Multiple Myeloma(4) (skip...) Phase 3:Finished: Diabetes Mellitus(77) Diabetes Mellitus, Type 2(67) Diphtheria(45) Whooping Cough(42) Tetanus(39) Influenza, Human(29) Meningococcal Infections(26) Hepatitis B(24) Poliomyelitis(22) Hepatitis(19) Depressive Disorder(19) (skip...) Phase 3:Abnormal: Influenza, Human(1) Colorectal Neoplasms(1) Phase 3:Aborted: Diabetes Mellitus, Type 2(14) Diabetes Mellitus(10) Hypercholesterolemia(4) Influenza, Human(3) Dyslipidemias(3) Recurrence(3) Atrial Fibrillation(3) Breast Neoplasms(2) Giant Cell Arteritis(2) Polymyalgia Rheumatica(2) Polycystic Kidney, Autosomal Dominant(2) (skip...) Phase 4:Ongoing: Asthma(2) Glycogen Storage Disease Type II(2) Eosinophilic Esophagitis(1) Esophagitis(1) Fabry Disease(1) Dermatitis(1) Dermatitis, Atopic(1) Diabetes Mellitus, Type 1(1) Diabetes Mellitus(1) Rhinitis, Allergic(1) Rhinitis(1) (skip...) Phase 4:Finished: Diabetes Mellitus, Type 2(65) Diabetes Mellitus(58) Influenza, Human(33) Diphtheria(20) Hypertension(18) Whooping Cough(17) Tetanus(16) Diabetes Mellitus, Type 1(12) Rhinitis, Allergic(10) Rhinitis(10) Tetany(10) (skip...) Phase 4:Aborted: Diabetes Mellitus, Type 2(7) Diabetes Mellitus(7) Atrial Fibrillation(3) Glycogen Storage Disease Type II(3) Fabry Disease(3) Pneumonia(3) Glycogen Storage Disease(2) Osteoporosis(2) Bronchitis, Chronic(2) Bronchitis(2) Infections(2) (skip...) Phase Not Applicable:Ongoing: Rare Diseases(1) Gaucher Disease(1) Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Phase Not Applicable:Finished: Lipidoses(1) Niemann-Pick Disease, Type C(1) Niemann-Pick Diseases(1) Niemann-Pick Disease, Type A(1) Hepatitis(1) Hepatitis B(1) Diabetes Mellitus(1) Osteoarthritis, Hip(1) Osteoarthritis(1) Alopecia Areata(1) Alopecia(1) (skip...) Phase Not Applicable:Aborted: Tissue Adhesions(2) Sinusitis(1) |
ALL | 8 | 73 | 58 | 11 | 47 | 2 | 30 | 48 |
| 2024 | 2 ⬤ | 7 ⬤ | 11 ⬤ | - | - | - | - | - | |||
| 2023 | 1 | 20 ⬤ | 9 ⬤ | 6 ⬤ | - | - | - | - | |||
| 2022 | 1 | 13 ⬤ | 8 ⬤ | - | - | - | - | - | |||
|
BMY
(Bristol-Myers Squibb Company) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(3) Liver Diseases(2) Neoplasms, Plasma Cell(2) Multiple Myeloma(2) Lymphoma, Non-Hodgkin(2) Lymphoma(2) Syndrome(2) Myelodysplastic Syndromes(2) Preleukemia(2) Leukemia, Myeloid, Acute(2) Leukemia, Myeloid(2) (skip...) Phase 1:Finished: Hepatitis C(20) Neoplasms(19) HIV Infections(17) Arthritis(16) Thrombosis(15) Arthritis, Rheumatoid(14) Alzheimer Disease(11) Melanoma(11) Psoriasis(9) Heart Failure(8) Carcinoma(8) (skip...) Phase 1:Abnormal: Glioblastoma(1) Phase 1:Aborted: Leukemia(5) Neoplasms(4) Melanoma(3) Leukemia, Lymphocytic, Chronic, B-Cell(3) Leukemia, Lymphoid(3) Lymphoma(3) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(3) Leukemia, Myeloid(3) Liver Diseases(2) Hypercholesterolemia(2) Hepatitis C(2) (skip...) Phase 2:Ongoing: Neoplasms(6) Carcinoma(5) Carcinoma, Non-Small-Cell Lung(4) Lung Neoplasms(4) Multiple Myeloma(4) Lupus Erythematosus, Systemic(3) Melanoma(3) Colorectal Neoplasms(3) Carcinoma, Hepatocellular(3) Neoplasms, Plasma Cell(3) Lymphoma(3) (skip...) Phase 2:Finished: Hepatitis(30) Hepatitis C(24) Hepatitis A(18) Melanoma(16) Leukemia(15) Carcinoma, Non-Small-Cell Lung(14) Breast Neoplasms(13) Arthritis(12) Lung Neoplasms(12) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(12) Leukemia, Myeloid(12) (skip...) Phase 2:Abnormal: Ketosis(1) Sclerosis(1) Multiple Sclerosis, Chronic Progressive(1) Multiple Sclerosis(1) Central Nervous System Neoplasms(1) Nervous System Neoplasms(1) Glioblastoma(1) Phase 2:Aborted: Carcinoma, Non-Small-Cell Lung(7) Lung Neoplasms(7) Hepatitis(6) Hepatitis C(6) Hepatitis A(5) Melanoma(5) Neoplasms(4) Hepatitis C, Chronic(4) Leukemia(4) Carcinoma(3) Breast Neoplasms(3) (skip...) Phase 3:Ongoing: Carcinoma, Non-Small-Cell Lung(6) Carcinoma(6) Melanoma(6) Hypertrophy(5) Cardiomyopathy, Hypertrophic(5) Cardiomyopathies(5) Lung Neoplasms(5) Syndrome(4) Carcinoma, Renal Cell(4) Myelodysplastic Syndromes(3) Preleukemia(3) (skip...) Phase 3:Finished: Hepatitis(35) Hepatitis C(24) Arthritis(24) Hepatitis A(24) Arthritis, Rheumatoid(22) HIV Infections(17) Melanoma(14) Hepatitis B(12) Lung Neoplasms(11) Hepatitis B, Chronic(10) Carcinoma(8) (skip...) Phase 3:Aborted: Hepatitis C(3) Hepatitis(3) Leukemia(3) Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Hepatitis A(2) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(2) Leukemia, Lymphoid(2) Leukemia, Lymphocytic, Chronic, B-Cell(1) Lymphoma(1) Liver Neoplasms(1) (skip...) Phase 4:Ongoing: Psoriasis(3) Sclerosis(1) Multiple Sclerosis(1) Hypertrophy(1) Cardiomyopathy, Hypertrophic(1) Cardiomyopathies(1) beta-Thalassemia(1) Thalassemia(1) Myelodysplastic Syndromes(1) Anemia(1) Preleukemia(1) (skip...) Phase 4:Finished: HIV Infections(4) Atrial Fibrillation(3) Hepatitis(3) Hepatitis B, Chronic(3) Hepatitis B(3) Syndrome(3) Diabetes Mellitus, Type 2(3) Kidney Neoplasms(2) Lung Neoplasms(2) Carcinoma, Renal Cell(2) Arthritis, Rheumatoid(2) (skip...) Phase 4:Aborted: Hepatitis(1) Hepatitis B, Chronic(1) Hepatitis B(1) Schizophrenia(1) Syndrome(1) Metabolic Syndrome(1) HIV Infections(1) Phase Not Applicable:Ongoing: Parkinson Disease(2) Critical Illness(1) Sclerosis(1) Tuberous Sclerosis(1) Parkinsonian Disorders(1) Lower Urinary Tract Symptoms(1) Urinary Bladder, Underactive(1) Hypokinesia(1) Phase Not Applicable:Finished: HIV Infections(11) Infections(8) Acquired Immunodeficiency Syndrome(8) Communicable Diseases(5) Obesity(4) Candidiasis(3) Lung Neoplasms(2) Pediatric Obesity(2) Diabetes Mellitus(2) Candidiasis, Oral(2) AIDS-Related Complex(2) (skip...) Phase Not Applicable:Abnormal: Depressive Disorder, Treatment-Resistant(1) Depressive Disorder(1) Depression(1) Phase Not Applicable:Aborted: Pain, Postoperative(1) Surgical Wound(1) Surgical Wound Infection(1) Wound Infection(1) Choledocholithiasis(1) |
ALL | 26 | 51 | 54 | 8 | 36 | 1 | 18 | 36 |
| 2024 | 5 ⬤ | 2 ⬤ | 2 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2023 | 13 ⬤ | 6 ⬤ | 7 ⬤ | 5 ⬤ | 1 | - | - | - | |||
| 2022 | 3 ⬤ | 12 ⬤ | 10 ⬤ | 2 ⬤ | 3 | - | - | 1 | |||
|
NVO
(Novo Nordisk A S) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Obesity(4) Liver Diseases(4) Diabetes Mellitus, Type 2(3) Diabetes Mellitus(2) Overweight(2) Fatty Liver(2) Thalassemia(1) Anemia, Sickle Cell(1) Non-alcoholic Fatty Liver Disease(1) Neoplasms(1) Dyslipidemias(1) (skip...) Phase 1:Finished: Diabetes Mellitus(149) Diabetes Mellitus, Type 2(108) Diabetes Mellitus, Type 1(69) Blood Coagulation Disorders(31) Hemostatic Disorders(31) Overweight(29) Hemophilia A(25) Obesity(21) Nutrition Disorders(19) Hemophilia B(14) Inflammation(7) (skip...) Phase 1:Aborted: Overweight(4) Inflammation(3) Nutrition Disorders(3) Blood Coagulation Disorders(2) Hemophilia A(2) Hemostatic Disorders(2) Obesity(2) Lupus Erythematosus, Systemic(2) Renal Insufficiency, Chronic(1) Kidney Diseases(1) Prostatic Neoplasms(1) (skip...) Phase 2:Ongoing: Diabetes Mellitus, Type 2(2) Obesity(2) Diabetes Mellitus(2) Amyloidosis(2) Cardiomyopathies(2) Hyperoxaluria, Primary(2) Liver Diseases(1) Overweight(1) Renal Insufficiency, Chronic(1) Kidney Diseases(1) Anemia, Sickle Cell(1) (skip...) Phase 2:Finished: Diabetes Mellitus(33) Diabetes Mellitus, Type 2(29) Blood Coagulation Disorders(19) Hemostatic Disorders(19) Hemorrhage(9) Hemophilia A(7) Inflammation(6) Diabetes Mellitus, Type 1(6) Hemophilia B(5) Overweight(4) Obesity(4) (skip...) Phase 2:Aborted: Inflammation(4) Arthritis, Rheumatoid(3) Arthritis(3) Hemorrhage(2) Blood Coagulation Disorders(2) Hemostatic Disorders(2) (1) Colitis, Ulcerative(1) Colitis(1) Diabetes Mellitus, Type 1(1) Diabetes Mellitus(1) (skip...) Phase 3:Ongoing: Diabetes Mellitus, Type 2(16) Diabetes Mellitus(16) Obesity(12) Hemophilia A(8) Overweight(5) Kidney Diseases(4) Inflammation(3) Alzheimer Disease(3) Hemophilia B(3) Renal Insufficiency, Chronic(3) Heart Failure(2) (skip...) Phase 3:Finished: Diabetes Mellitus(188) Diabetes Mellitus, Type 2(147) Diabetes Mellitus, Type 1(49) Blood Coagulation Disorders(22) Hemostatic Disorders(22) Obesity(21) Hemophilia A(17) Overweight(17) Dwarfism, Pituitary(12) Nutrition Disorders(10) Hemorrhage(10) (skip...) Phase 3:Aborted: Diabetes Mellitus(15) Diabetes Mellitus, Type 2(14) Diabetes Mellitus, Type 1(3) Hemorrhage(2) Blood Coagulation Disorders(2) Hemostatic Disorders(2) Hemophilia A(1) Urinary Tract Infections(1) Communicable Diseases(1) Infections(1) Asthma(1) (skip...) Phase 4:Ongoing: Obesity(1) Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Phase 4:Finished: Diabetes Mellitus(76) Diabetes Mellitus, Type 2(70) Diabetes Mellitus, Type 1(11) Blood Coagulation Disorders(4) Hemophilia A(4) Hemostatic Disorders(4) Genetic Diseases, Inborn(3) Turner Syndrome(3) Hemophilia B(3) Fetal Growth Retardation(2) Syndrome(2) (skip...) Phase 4:Aborted: Diabetes Mellitus(4) Diabetes Mellitus, Type 2(3) Endocrine System Diseases(1) Dwarfism, Pituitary(1) Diabetes Mellitus, Type 1(1) Phase Not Applicable:Finished: Diabetes Mellitus, Type 1(1) Diabetes Mellitus(1) |
ALL | 23 | 13 | 47 | 2 | 8 | - | 6 | 15 |
| 2024 | 12 ⬤ | 4 ⬤ | 6 ⬤ | - | - | - | - | - | |||
| 2023 | 7 | 1 ⬤ | 14 ⬤ | - | 1 | - | - | - | |||
| 2022 | 4 ⬤ | 2 ⬤ | 10 ⬤ | 1 | - | - | - | - | |||
|
AMGN
(Amgen Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(4) Dermatitis(3) Lung Neoplasms(3) Prostatic Neoplasms(3) Small Cell Lung Carcinoma(3) Leukemia(2) Kidney Failure, Chronic(1) Kidney Diseases(1) Thyroid Diseases(1) Graves Ophthalmopathy(1) Eye Diseases(1) (skip...) Phase 1:Finished: Neoplasms(18) Lupus Erythematosus, Systemic(10) Multiple Myeloma(7) Migraine Disorders(6) Renal Insufficiency(6) Kidney Diseases(6) Bone Diseases, Metabolic(6) Neoplasms, Plasma Cell(6) Lymphoma(6) Vasculitis(5) Liver Diseases(5) (skip...) Phase 1:Abnormal: Small Cell Lung Carcinoma(1) Lung Neoplasms(1) Phase 1:Aborted: Leukemia, Myeloid, Acute(5) Leukemia, Myeloid(5) Leukemia(5) Multiple Myeloma(5) Neoplasms, Plasma Cell(4) Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Neoplasms(3) Carcinoma, Non-Small-Cell Lung(3) Adenocarcinoma(2) Asthma(2) (skip...) Phase 2:Ongoing: Neoplasms(3) (2) Colitis, Ulcerative(2) Colitis(2) Carcinoma, Non-Small-Cell Lung(2) Sclerosis(2) Scleroderma, Diffuse(2) Scleroderma, Systemic(2) Leukemia, Lymphoid(2) Precursor Cell Lymphoblastic Leukemia-Lymphoma(2) Leukemia(2) (skip...) Phase 2:Finished: Colorectal Neoplasms(16) Lung Neoplasms(13) Anemia(13) Neoplasms(13) Arthritis(12) Carcinoma(11) Lymphoma(11) Multiple Myeloma(11) Breast Neoplasms(9) Neoplasm Metastasis(9) Carcinoma, Non-Small-Cell Lung(9) (skip...) Phase 2:Abnormal: Lung Neoplasms(1) Prostatic Neoplasms(1) Lymphoma, Non-Hodgkin(1) Lymphoma(1) Ureteral Neoplasms(1) Kidney Neoplasms(1) Carcinoma, Transitional Cell(1) Urinary Bladder Neoplasms(1) Phase 2:Aborted: Multiple Myeloma(4) Arthritis, Rheumatoid(4) Arthritis(4) Neoplasms, Plasma Cell(3) Adenocarcinoma(3) Anemia(3) Schizophrenia(2) Crohn Disease(2) Neoplasms(2) Lupus Erythematosus, Systemic(2) Lupus Nephritis(1) (skip...) Phase 3:Ongoing: Eczema(8) Dermatitis(8) Dermatitis, Atopic(8) Lung Neoplasms(7) Psoriasis(5) Carcinoma, Non-Small-Cell Lung(5) Small Cell Lung Carcinoma(3) Colorectal Neoplasms(3) Syndrome(2) Sjogren\'s Syndrome(2) Melanoma(2) (skip...) Phase 3:Finished: Kidney Diseases(26) Arthritis(22) Renal Insufficiency, Chronic(22) Osteoporosis(21) Psoriasis(21) Neoplasm Metastasis(18) Hyperparathyroidism(16) Arthritis, Rheumatoid(14) Hypercholesterolemia(13) Anemia(13) Hyperparathyroidism, Secondary(13) (skip...) Phase 3:Aborted: Renal Insufficiency, Chronic(5) Kidney Diseases(5) Anemia(4) Carcinoma, Non-Small-Cell Lung(3) Lung Neoplasms(3) Dyslipidemias(2) Osteogenesis Imperfecta(2) Stomach Neoplasms(2) Fallopian Tube Neoplasms(2) Carcinoma, Ovarian Epithelial(2) Ovarian Neoplasms(2) (skip...) Phase 4:Ongoing: Osteoporosis(2) (1) Neuromyelitis Optica(1) Osteoporosis, Postmenopausal(1) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis(1) Vasculitis(1) Infarction(1) Myocardial Infarction(1) Cardiovascular Diseases(1) Graves Ophthalmopathy(1) Eye Diseases(1) (skip...) Phase 4:Finished: Arthritis(14) Kidney Diseases(11) Arthritis, Rheumatoid(10) Psoriasis(9) Renal Insufficiency, Chronic(8) Hyperparathyroidism(6) Migraine Disorders(5) Hyperparathyroidism, Secondary(5) Renal Insufficiency(5) Kidney Failure, Chronic(5) Anemia(5) (skip...) Phase 4:Aborted: Arthritis, Rheumatoid(2) Arthritis(2) Migraine Disorders(1) Bone Diseases(1) Anemia(1) Psoriasis(1) Phase Not Applicable:Finished: Atherosclerosis(1) Cardiovascular Diseases(1) Syndrome(1) Thrombocytopenia(1) Myelodysplastic Syndromes(1) Preleukemia(1) Anemia(1) Heart Failure(1) HIV Infections(1) AIDS-Related Complex(1) Mycobacterium avium-intracellulare Infection(1) (skip...) Phase Not Applicable:Aborted: Heart Failure(1) |
ALL | 23 | 20 | 45 | 10 | 16 | 1 | 1 | 6 |
| 2024 | 8 ⬤ | 2 ⬤ | 8 ⬤ | 2 ⬤ | - | - | - | - | |||
| 2023 | 3 ⬤ | 3 ⬤ | 14 ⬤ | 3 ⬤ | - | - | - | 2 | |||
| 2022 | 3 ⬤ | 6 ⬤ | 6 ⬤ | 1 ⬤ | - | - | - | - | |||
|
TAK
(Takeda Pharmaceutical Company Limited) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(3) Liver Diseases(2) Neoplasms, Plasma Cell(2) Multiple Myeloma(2) Lupus Nephritis(1) Nephritis(1) Glomerulonephritis(1) Kidney Diseases(1) Carcinoma, Non-Small-Cell Lung(1) Lung Neoplasms(1) Phase 1:Finished: Gastroesophageal Reflux(6) Liver Diseases(5) Diabetes Mellitus(4) Esophagitis, Peptic(4) Renal Insufficiency(3) Diabetes Mellitus, Type 2(3) Neoplasms(3) Narcolepsy(2) Epilepsy(2) Esophagitis(2) Schizophrenia(2) (skip...) Phase 1:Aborted: Neoplasms, Plasma Cell(2) Multiple Myeloma(2) Cognitive Dysfunction(2) Schizophrenia(2) Coronavirus Infections(1) Alzheimer Disease(1) Gastroesophageal Reflux(1) Lupus Nephritis(1) Nephritis(1) Attention Deficit Disorder with Hyperactivity(1) Hyperkinesis(1) (skip...) Phase 2:Ongoing: Leukemia(4) (3) Lymphoma(3) Multiple Myeloma(3) Leukemia, Myeloid(3) Carcinoma, Squamous Cell(2) Neoplasms, Squamous Cell(2) Neoplasm Metastasis(2) Celiac Disease(2) Neoplasms(2) Leukemia, Myeloid, Acute(2) (skip...) Phase 2:Finished: Diabetes Mellitus(11) Diabetes Mellitus, Type 2(7) Dengue(6) Hypertension(5) Renal Insufficiency(5) (5) Arthritis(4) Sleep Initiation and Maintenance Disorders(4) Carcinoma(3) Gastroesophageal Reflux(3) Arthritis, Rheumatoid(3) (skip...) Phase 2:Aborted: Narcolepsy(2) Lymphoma, Non-Hodgkin(2) Lymphoma(2) Neoplasms(2) Neoplasms, Plasma Cell(2) Multiple Myeloma(2) Crohn Disease(2) Recurrence(2) Arthritis, Rheumatoid(2) Arthritis(2) Diabetes Mellitus(2) (skip...) Phase 3:Ongoing: Crohn Disease(9) (7) Colitis, Ulcerative(7) Colitis(7) Syndrome(4) Psoriasis(3) Alpha 1-Antitrypsin Deficiency(3) Liver Diseases(3) Immunologic Deficiency Syndromes(3) Primary Immunodeficiency Diseases(3) Cytomegalovirus Infections(2) (skip...) Phase 3:Finished: Diabetes Mellitus(39) Diabetes Mellitus, Type 2(24) (23) Hypertension(22) Essential Hypertension(17) Esophagitis, Peptic(15) Gastroesophageal Reflux(15) Depressive Disorder, Major(13) Depression(13) Depressive Disorder(13) Disease(12) (skip...) Phase 3:Aborted: Diabetes Mellitus(15) Diabetes Mellitus, Type 2(12) Hypercholesterolemia(4) Bipolar Disorder(3) Cognitive Dysfunction(2) Alzheimer Disease(2) Hypertension(2) Heart Failure(2) Constipation(1) Cholangitis, Sclerosing(1) Cholangitis(1) (skip...) Phase 4:Ongoing: Crohn Disease(3) Mucopolysaccharidosis II(3) Syndrome(2) Mucopolysaccharidoses(2) Lymphoma(2) Surgical Wound Infection(1) Communicable Diseases(1) Infections(1) (1) Colitis, Ulcerative(1) Colitis(1) (skip...) Phase 4:Finished: Diabetes Mellitus(13) Diabetes Mellitus, Type 2(7) Gastroesophageal Reflux(6) Esophagitis, Peptic(5) Crohn Disease(4) Hypertension(4) Sleep Initiation and Maintenance Disorders(4) (3) Colitis, Ulcerative(3) Colitis(3) Depressive Disorder, Major(3) (skip...) Phase 4:Aborted: (2) Colitis, Ulcerative(2) Colitis(2) Crohn Disease(2) Emphysema(1) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases, Obstructive(1) Lung Diseases(1) Alpha 1-Antitrypsin Deficiency(1) Neoplasms, Plasma Cell(1) Multiple Myeloma(1) (skip...) Phase Not Applicable:Finished: Hemophilia A(1) Celiac Disease(1) |
ALL | 13 | 30 | 43 | 12 | 23 | 1 | 13 | 8 |
| 2024 | 3 ⬤ | 3 ⬤ | 6 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2023 | 4 ⬤ | 4 ⬤ | 12 ⬤ | 2 ⬤ | 1 | - | - | 1 | |||
| 2022 | 1 ⬤ | 4 ⬤ | 8 ⬤ | 3 | - | - | - | - | |||
|
REGN
(Regeneron Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(3) Non-alcoholic Fatty Liver Disease(2) Fatty Liver(2) Liver Diseases(2) Lymphoma(2) Fallopian Tube Neoplasms(1) Carcinoma, Ovarian Epithelial(1) Ovarian Neoplasms(1) Hemorrhage(1) Food Hypersensitivity(1) Hypersensitivity(1) (skip...) Phase 1:Finished: Arthritis(5) Dermatitis(4) Dermatitis, Atopic(4) Arthritis, Rheumatoid(4) Neoplasms(4) Macular Degeneration(4) Lymphoma(4) COVID-19(3) Melanoma(3) Asthma(2) Eczema(2) (skip...) Phase 1:Aborted: COVID-19(2) Neoplasms(2) Carcinoma, Non-Small-Cell Lung(1) Lung Neoplasms(1) Diabetes Mellitus, Type 2(1) Diabetes Mellitus(1) Phase 2:Ongoing: Neoplasms, Plasma Cell(5) Multiple Myeloma(5) Carcinoma, Non-Small-Cell Lung(4) Lung Neoplasms(4) Carcinoma(3) Venous Thromboembolism(2) Thromboembolism(2) Smoldering Multiple Myeloma(2) Heart Failure(2) Carcinoma, Squamous Cell(2) Carcinoma, Renal Cell(2) (skip...) Phase 2:Finished: Eczema(6) Dermatitis(6) Dermatitis, Atopic(6) Hypercholesterolemia(5) Macular Degeneration(4) Hemoglobinuria, Paroxysmal(3) Hemoglobinuria(3) Carcinoma(3) Hyperlipoproteinemia Type II(3) COVID-19(2) Peanut Hypersensitivity(2) (skip...) Phase 2:Abnormal: Carcinoma, Basal Cell(1) Neoplasm Metastasis(1) Triple Negative Breast Neoplasms(1) Carcinoma, Squamous Cell(1) Carcinoma(1) Carcinoma, Merkel Cell(1) Phase 2:Aborted: Eczema(3) Dermatitis(3) Dermatitis, Atopic(3) Osteoarthritis, Knee(3) Osteoarthritis(3) Pancreatitis(2) Carcinoma, Non-Small-Cell Lung(2) Lipodystrophy(1) Lipodystrophy, Familial Partial(1) Congenital Abnormalities(1) COVID-19(1) (skip...) Phase 3:Ongoing: Lymphoma(5) Melanoma(5) Carcinoma, Non-Small-Cell Lung(4) Lung Neoplasms(4) Lymphoma, Follicular(3) Lymphoma, B-Cell(2) Hemoglobinuria, Paroxysmal(2) Hemoglobinuria(2) Macular Edema(2) Eosinophilic Esophagitis(2) Carcinoma(2) (skip...) Phase 3:Finished: Dermatitis(10) Hypercholesterolemia(10) Dermatitis, Atopic(9) Hyperlipoproteinemia Type II(6) (6) Eczema(5) Osteoarthritis, Knee(4) Osteoarthritis(4) Osteoarthritis, Hip(3) COVID-19(2) Homozygous Familial Hypercholesterolemia(2) (skip...) Phase 3:Aborted: COVID-19(2) Hemoglobinuria, Paroxysmal(2) Hemoglobinuria(2) Rhinitis, Allergic(1) Rhinitis(1) Ossification, Heterotopic(1) Myositis Ossificans(1) Carcinoma, Non-Small-Cell Lung(1) Lung Neoplasms(1) Low Back Pain(1) Back Pain(1) (skip...) Phase 4:Ongoing: Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Phase 4:Finished: Asthma(1) Vascular Diseases(1) Hypercholesterolemia(1) Macular Degeneration(1) (1) Phase 4:Aborted: Hypercholesterolemia(1) Hyperlipoproteinemia Type II(1) Phase Not Applicable:Ongoing: Celiac Disease(1) Phase Not Applicable:Finished: Hemorrhage(1) Phase Not Applicable:Aborted: Non-alcoholic Fatty Liver Disease(1) Fatty Liver(1) |
ALL | 19 | 35 | 26 | 1 | 7 | - | - | 1 |
| 2024 | 5 ⬤ | 10 ⬤ | 1 ⬤ | - | - | - | - | - | |||
| 2023 | 4 ⬤ | 5 ⬤ | 12 ⬤ | - | 1 | - | - | 1 | |||
| 2022 | 4 ⬤ | 3 ⬤ | 3 ⬤ | 1 ⬤ | - | - | - | - | |||
|
GILD
(Gilead Sciences Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(6) Hepatitis D, Chronic(2) Hepatitis D(2) Lymphoma, B-Cell(2) Lymphoma(2) Arthritis, Rheumatoid(1) Arthritis(1) Hepatitis, Chronic(1) Hepatitis(1) Hepatitis B, Chronic(1) Hepatitis B(1) (skip...) Phase 1:Finished: Hepatitis C(12) Hepatitis(10) Hepatitis A(8) HIV Infections(8) Hepatitis C, Chronic(6) Long QT Syndrome(5) Fibrosis(5) Leukemia, Lymphocytic, Chronic, B-Cell(5) Renal Insufficiency(4) Arthritis, Rheumatoid(4) Arthritis(4) (skip...) Phase 1:Abnormal: HIV Infections(1) Phase 1:Aborted: Lymphoma(8) Leukemia(7) Neoplasms(5) Leukemia, Lymphoid(5) Leukemia, Lymphocytic, Chronic, B-Cell(4) Lymphoma, B-Cell(3) Neoplasms, Plasma Cell(3) Multiple Myeloma(3) Adenocarcinoma(3) Fibrosis(3) Lymphoma, Non-Hodgkin(3) (skip...) Phase 2:Ongoing: Lymphoma(5) Triple Negative Breast Neoplasms(3) Breast Neoplasms(3) Neoplasms(3) (2) Colitis, Ulcerative(2) Colitis(2) HIV Infections(2) Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Lymphoma, Mantle-Cell(2) (skip...) Phase 2:Finished: Hepatitis C(57) Hepatitis(45) Infections(35) Hepatitis A(32) Communicable Diseases(24) Hepatitis, Chronic(17) Hepatitis B(16) Hepatitis C, Chronic(15) Hepatitis B, Chronic(13) Lymphoma(13) HIV Infections(9) (skip...) Phase 2:Abnormal: HIV Infections(1) Phase 2:Aborted: Lymphoma(9) Leukemia, Lymphocytic, Chronic, B-Cell(8) Leukemia, Lymphoid(7) Leukemia(7) Lymphoma, Non-Hodgkin(6) Fibrosis(5) Hepatitis(4) Colorectal Neoplasms(3) Hepatitis A(3) Lymphoma, Large B-Cell, Diffuse(3) Hepatitis C(3) (skip...) Phase 3:Ongoing: HIV Infections(6) Breast Neoplasms(5) Communicable Diseases(4) Infections(4) Acquired Immunodeficiency Syndrome(4) Triple Negative Breast Neoplasms(3) Lymphoma(3) Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Lymphoma, B-Cell(2) Immunologic Deficiency Syndromes(2) (skip...) Phase 3:Finished: Hepatitis C(43) Infections(33) Hepatitis(33) HIV Infections(26) Communicable Diseases(21) Hepatitis A(19) Acquired Immunodeficiency Syndrome(13) Hepatitis B(13) Hepatitis C, Chronic(11) Immunologic Deficiency Syndromes(10) Fibrosis(9) (skip...) Phase 3:Abnormal: Lymphoma, Non-Hodgkin(2) Lymphoma(2) HIV Infections(1) Phase 3:Aborted: Leukemia(6) COVID-19(4) Leukemia, Lymphocytic, Chronic, B-Cell(4) Leukemia, Lymphoid(4) Lymphoma(3) Fibrosis(3) Hypertension(3) Leukemia, Myeloid, Acute(2) Leukemia, Myeloid(2) Spondylitis, Ankylosing(2) Spondylitis(2) (skip...) Phase 4:Ongoing: Infections(1) Neoplasms(1) Phase 4:Finished: HIV Infections(12) Infections(4) Hepatitis, Chronic(3) Hepatitis(3) Hepatitis B, Chronic(3) Hepatitis B(3) Myocardial Ischemia(2) Hepatitis A(2) Angina Pectoris(2) Hepatitis C(1) Diabetes Mellitus(1) (skip...) Phase 4:Aborted: Coronary Disease(2) Myocardial Ischemia(2) Coronary Artery Disease(2) Neoplasms(1) Hepatitis(1) Hepatitis B, Chronic(1) Hepatitis B(1) Hepatitis A(1) Diabetes Mellitus(1) Angina, Stable(1) Angina Pectoris(1) (skip...) Phase Not Applicable:Finished: HIV Infections(5) Acquired Immunodeficiency Syndrome(2) Infections(2) Herpes Simplex(1) Retinitis(1) Cytomegalovirus Retinitis(1) Phase Not Applicable:Abnormal: HIV Infections(1) Retinitis(1) Cytomegalovirus Retinitis(1) Phase Not Applicable:Aborted: Hepatitis(1) Hepatitis B(1) |
ALL | 15 | 30 | 24 | 3 | 17 | - | 6 | 9 |
| 2024 | - | 2 ⬤ | 2 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2023 | 8 ⬤ | 4 ⬤ | 1 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2022 | 1 ⬤ | 7 ⬤ | 7 ⬤ | - | 2 | - | - | - | |||
|
INCY
(Incyte Corp.) commercial physical/biological research or service Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(14) Myeloproliferative Disorders(4) Carcinoma(4) Carcinoma, Squamous Cell(3) Carcinoma, Renal Cell(2) Small Cell Lung Carcinoma(2) Carcinoma, Merkel Cell(2) Neurodermatitis(1) Prurigo(1) Microsatellite Instability(1) Colorectal Neoplasms(1) (skip...) Phase 1:Finished: Neoplasms(10) Renal Insufficiency(4) Lymphoma(4) Lymphoma, B-Cell(3) Eczema(3) Dermatitis(3) Dermatitis, Atopic(3) Kidney Diseases(2) Carcinoma(2) Graft vs Host Disease(2) Hematologic Neoplasms(2) (skip...) Phase 1:Aborted: Carcinoma, Non-Small-Cell Lung(2) Carcinoma(2) Mesothelioma(1) Sarcoma, Ewing(1) Sarcoma(1) Graft vs Host Disease(1) Hematologic Neoplasms(1) Nasopharyngeal Carcinoma(1) Nasopharyngeal Neoplasms(1) Cholangiocarcinoma(1) Carcinoma, Hepatocellular(1) (skip...) Phase 2:Ongoing: Neoplasms(6) Lymphoma(5) Lymphoma, Non-Hodgkin(2) Graft vs Host Disease(2) Bronchiolitis Obliterans Syndrome(2) Thrombocytosis(2) Polycythemia(2) Primary Myelofibrosis(2) Anemia(2) Polycythemia Vera(2) Carcinoma(2) (skip...) Phase 2:Finished: Primary Myelofibrosis(7) Polycythemia Vera(5) Hidradenitis(4) Hidradenitis Suppurativa(4) Carcinoma, Non-Small-Cell Lung(4) Vitiligo(4) Carcinoma(4) Psoriasis(4) Thrombocytosis(4) Polycythemia(4) Lung Neoplasms(3) (skip...) Phase 2:Aborted: Neoplasms(11) Myeloproliferative Disorders(4) Carcinoma(3) Hematologic Neoplasms(3) Carcinoma, Non-Small-Cell Lung(3) Breast Neoplasms(3) Carcinoma, Transitional Cell(2) Multiple Myeloma(2) Lung Neoplasms(2) Syndrome(2) Thrombocythemia, Essential(2) (skip...) Phase 3:Ongoing: Thrombocythemia, Essential(4) Thrombocytosis(4) Polycythemia(4) Primary Myelofibrosis(4) Polycythemia Vera(4) Hidradenitis(3) Hidradenitis Suppurativa(3) Carcinoma(3) Vitiligo(2) Prurigo(2) Eczema(2) (skip...) Phase 3:Finished: Vitiligo(3) Eczema(3) Dermatitis(3) Dermatitis, Atopic(3) Polycythemia Vera(3) Carcinoma, Transitional Cell(2) Graft vs Host Disease(2) Polycythemia(2) Carcinoma(1) Melanoma(1) Myeloproliferative Disorders(1) (skip...) Phase 3:Aborted: Eczema(2) Lymphoma(2) Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Pancreatic Neoplasms(2) Hemolysis(1) Anemia, Hemolytic, Autoimmune(1) Anemia, Hemolytic(1) Anemia(1) Lymphoma, Mantle-Cell(1) Lymphoma, B-Cell, Marginal Zone(1) (skip...) Phase 4:Ongoing: Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Parasomnias(1) Dyssomnias(1) |
ALL | 21 | 28 | 21 | 1 | 3 | - | - | 1 |
| 2024 | 6 ⬤ | 2 ⬤ | 3 ⬤ | - | - | - | - | - | |||
| 2023 | 7 ⬤ | 7 ⬤ | 4 ⬤ | 1 | 1 | - | - | - | |||
| 2022 | 2 ⬤ | 1 | 4 ⬤ | - | - | - | - | - | |||
|
BGNE
(BeiGene Ltd.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(14) Carcinoma, Non-Small-Cell Lung(3) Breast Neoplasms(3) Stomach Neoplasms(2) Lung Neoplasms(2) Carcinoma(2) Carcinoma, Hepatocellular(1) Autoimmune Diseases(1) Endometrial Neoplasms(1) Small Cell Lung Carcinoma(1) Ovarian Neoplasms(1) (skip...) Phase 1:Finished: Neoplasms(8) Lymphoma, B-Cell(2) Lymphoma(2) Neuroblastoma(1) COVID-19(1) Lymphoma, Large B-Cell, Diffuse(1) Liver Failure(1) Hepatic Insufficiency(1) Phase 1:Aborted: Neoplasms(1) Phase 2:Ongoing: Lymphoma(10) Neoplasms(6) Lymphoma, Mantle-Cell(5) Leukemia, Lymphocytic, Chronic, B-Cell(5) Carcinoma, Non-Small-Cell Lung(4) Lung Neoplasms(4) Carcinoma(4) Lymphoma, Large B-Cell, Diffuse(4) Waldenstrom Macroglobulinemia(4) Carcinoma, Squamous Cell(3) Colorectal Neoplasms(2) (skip...) Phase 2:Finished: Lymphoma(7) Carcinoma(6) Neoplasms(4) Carcinoma, Hepatocellular(3) COVID-19(2) Lymphoma, B-Cell, Marginal Zone(2) Esophageal Squamous Cell Carcinoma(2) Lung Neoplasms(2) Stomach Neoplasms(2) Breast Neoplasms(2) Lymphoma, Large B-Cell, Diffuse(2) (skip...) Phase 2:Aborted: Esophageal Squamous Cell Carcinoma(1) Carcinoma, Squamous Cell(1) Carcinoma(1) Prostatic Neoplasms(1) Neoplasms(1) Phase 3:Ongoing: Lymphoma(4) Carcinoma(3) Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Neoplasms(2) Esophageal Squamous Cell Carcinoma(2) Carcinoma, Squamous Cell(2) Leukemia, Lymphocytic, Chronic, B-Cell(2) Leukemia, Lymphoid(2) Leukemia(2) Glomerulonephritis, Membranous(1) (skip...) Phase 3:Finished: Lung Neoplasms(4) Carcinoma, Non-Small-Cell Lung(3) Carcinoma(2) Small Cell Lung Carcinoma(1) Leukemia, Lymphocytic, Chronic, B-Cell(1) Leukemia, Lymphoid(1) Leukemia(1) Lymphoma(1) Esophageal Squamous Cell Carcinoma(1) Carcinoma, Squamous Cell(1) Carcinoma, Hepatocellular(1) (skip...) Phase 3:Aborted: Carcinoma, Non-Small-Cell Lung(2) Lung Neoplasms(2) Carcinoma, Hepatocellular(1) Carcinoma(1) |
ALL | 20 | 29 | 16 | - | 1 | - | - | - |
| 2024 | 6 ⬤ | - | - | - | - | - | - | - | |||
| 2023 | 6 ⬤ | 4 ⬤ | 2 ⬤ | - | - | - | - | - | |||
| 2022 | 2 ⬤ | 8 ⬤ | - | - | - | - | - | - | |||
|
VRTX
(Vertex Pharmaceuticals Incorporated) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Cystic Fibrosis(2) Polycystic Kidney, Autosomal Dominant(1) Polycystic Kidney Diseases(1) Kidney Diseases(1) Renal Insufficiency(1) Phase 1:Finished: Cystic Fibrosis(17) Hepatitis C(7) Alpha 1-Antitrypsin Deficiency(2) Hepatitis C, Chronic(2) Hepatitis(2) Hepatitis A(2) Glomerulosclerosis, Focal Segmental(1) Renal Insufficiency(1) Acute Pain(1) Kidney Diseases(1) Fibrosis(1) (skip...) Phase 2:Ongoing: Diabetes Mellitus, Type 1(2) Diabetes Mellitus(2) Myotonic Dystrophy(1) (1) Radiculopathy(1) Fibrosis(1) Cystic Fibrosis(1) Alpha 1-Antitrypsin Deficiency(1) Hypoglycemia(1) Phase 2:Finished: Fibrosis(19) Cystic Fibrosis(19) Hepatitis(13) Hepatitis C(13) Hepatitis A(13) Hepatitis C, Chronic(9) Arthritis, Rheumatoid(5) Arthritis(5) Acute Pain(4) Hepatitis, Chronic(4) Diabetic Neuropathies(1) (skip...) Phase 2:Aborted: Hepatitis(3) Hepatitis C(3) Hepatitis A(2) Fibrosis(2) Cystic Fibrosis(2) Alpha 1-Antitrypsin Deficiency(1) Epilepsies, Partial(1) Epilepsy(1) Virus Diseases(1) Hepatitis C, Chronic(1) Infections(1) (skip...) Phase 3:Ongoing: Fibrosis(7) Cystic Fibrosis(7) Hemoglobinopathies(6) Hematologic Diseases(6) Anemia, Sickle Cell(5) Genetic Diseases, Inborn(4) beta-Thalassemia(4) Thalassemia(4) Kidney Diseases(1) Phase 3:Finished: Fibrosis(52) Cystic Fibrosis(52) Acute Pain(3) Hepatitis(2) Hepatitis C(2) Hepatitis A(2) Lung Diseases(1) Arthritis, Rheumatoid(1) Arthritis(1) Hepatitis C, Chronic(1) Phase 3:Aborted: Fibrosis(3) Cystic Fibrosis(3) Hepatitis(2) Hepatitis C(2) Wounds and Injuries(1) Spinal Cord Injuries(1) Hepatitis A(1) Hepatitis C, Chronic(1) Phase 4:Finished: Fibrosis(1) Cystic Fibrosis(1) Phase 4:Aborted: Cystic Fibrosis(1) Hepatitis(1) Hepatitis C, Chronic(1) Hepatitis C(1) Hepatitis A(1) Phase Not Applicable:Aborted: Neoplasms(1) |
ALL | 9 | 6 | 15 | - | 5 | - | 3 | - |
| 2024 | 6 ⬤ | - | 1 ⬤ | - | - | - | - | - | |||
| 2023 | 3 ⬤ | 3 ⬤ | 3 ⬤ | - | - | - | 1 | - | |||
| 2022 | - | 2 ⬤ | 7 ⬤ | - | - | - | - | - | |||
|
BIIB
(Biogen Idec Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Friedreich Ataxia(1) Cerebellar Ataxia(1) Ataxia(1) Muscular Atrophy, Spinal(1) Muscular Atrophy(1) Parkinson Disease(1) Phase 1:Finished: Multiple Sclerosis(13) Sclerosis(8) Neoplasms(7) Neuralgia(5) Schizophrenia(4) Atrophy(4) Alzheimer Disease(4) Multiple Sclerosis, Relapsing-Remitting(4) Trigeminal Neuralgia(3) Muscular Atrophy, Spinal(3) Muscular Atrophy(3) (skip...) Phase 1:Aborted: Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Renal Insufficiency, Chronic(3) Kidney Diseases(3) Renal Insufficiency(2) Leukemia, Lymphocytic, Chronic, B-Cell(2) Leukemia, Lymphoid(2) Leukemia(2) Machado-Joseph Disease(1) Spinocerebellar Degenerations(1) Spinocerebellar Ataxias(1) (skip...) Phase 2:Ongoing: Sclerosis(2) Diabetic Neuropathies(1) Neuralgia(1) Multiple Sclerosis(1) Cognitive Dysfunction(1) Dementia(1) Alzheimer Disease(1) Parkinson Disease(1) Disease Progression(1) Amyotrophic Lateral Sclerosis(1) Motor Neuron Disease(1) (skip...) Phase 2:Finished: Multiple Sclerosis(15) Sclerosis(14) Multiple Sclerosis, Relapsing-Remitting(9) Kidney Diseases(5) Renal Insufficiency, Chronic(4) Radiculopathy(3) Neuralgia(3) Parkinson Disease(3) Arthritis, Rheumatoid(3) Arthritis(3) Depressive Disorder, Major(2) (skip...) Phase 2:Aborted: Arthritis, Rheumatoid(7) Arthritis(7) Sclerosis(4) Multiple Sclerosis(4) Diabetes Mellitus(3) Alzheimer Disease(2) Cognitive Dysfunction(2) Diabetes Mellitus, Type 2(2) Lupus Nephritis(2) Nephritis(2) Renal Insufficiency(2) (skip...) Phase 3:Ongoing: Lupus Erythematosus, Systemic(5) Sclerosis(3) Multiple Sclerosis(3) Lupus Erythematosus, Discoid(2) Lupus Erythematosus, Cutaneous(2) Atrophy(2) Muscular Atrophy, Spinal(2) Muscular Atrophy(2) Alzheimer Disease(2) Multiple Sclerosis, Relapsing-Remitting(2) Amyotrophic Lateral Sclerosis(1) (skip...) Phase 3:Finished: Sclerosis(27) Multiple Sclerosis(26) Multiple Sclerosis, Relapsing-Remitting(16) Depressive Disorder(5) Depression(5) Depressive Disorder, Major(3) Atrophy(3) Muscular Atrophy, Spinal(3) Muscular Atrophy(3) Crohn Disease(3) Depression, Postpartum(2) (skip...) Phase 3:Aborted: Sclerosis(11) Multiple Sclerosis(11) Multiple Sclerosis, Relapsing-Remitting(7) Lymphoma, Non-Hodgkin(3) Lymphoma(3) Depressive Disorder, Major(2) Depression(2) Depressive Disorder(2) Polycystic Kidney, Autosomal Dominant(2) Polycystic Kidney Diseases(2) Neuralgia(2) (skip...) Phase 4:Ongoing: Sclerosis(1) Multiple Sclerosis(1) Atrophy(1) Muscular Atrophy, Spinal(1) Muscular Atrophy(1) Phase 4:Finished: Multiple Sclerosis(24) Sclerosis(21) Multiple Sclerosis, Relapsing-Remitting(15) Lymphoma, Non-Hodgkin(2) Lymphoma(2) Injection Site Reaction(1) Flushing(1) Crohn Disease(1) Phase 4:Aborted: Multiple Sclerosis(10) Sclerosis(9) Multiple Sclerosis, Relapsing-Remitting(7) Erythema(1) Fatigue(1) Syndrome(1) Immune Reconstitution Inflammatory Syndrome(1) Leukoencephalopathies(1) Leukoencephalopathy, Progressive Multifocal(1) Crohn Disease(1) Phase Not Applicable:Ongoing: Atrophy(1) Muscular Atrophy, Spinal(1) Muscular Atrophy(1) Phase Not Applicable:Finished: Atrophy(1) Neuromuscular Diseases(1) Muscular Atrophy, Spinal(1) Muscular Atrophy(1) Sclerosis(1) Multiple Sclerosis(1) |
ALL | 5 | 7 | 15 | 2 | 8 | 1 | - | 1 |
| 2024 | 2 ⬤ | - | - | - | - | - | - | - | |||
| 2023 | 1 | 1 ⬤ | 1 ⬤ | - | 1 | - | - | 1 | |||
| 2022 | 1 ⬤ | 3 ⬤ | 3 ⬤ | 1 ⬤ | - | - | - | - | |||
|
SBFM
(Sunshine Biopharma Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Renal Insufficiency, Chronic(3) Kidney Diseases(3) Diabetes Mellitus, Type 2(2) Neoplasms(2) Sleep Initiation and Maintenance Disorders(2) Pulmonary Eosinophilia(2) Acne Vulgaris(1) Arthritis, Gouty(1) Asthma(1) Thrombocytopenia(1) Liver Diseases(1) (skip...) Phase 1:Finished: Hepatitis C, Chronic(6) Hepatitis C(6) Idiopathic Pulmonary Fibrosis(4) Pulmonary Fibrosis(4) Non-alcoholic Fatty Liver Disease(3) Fatty Liver(3) Hepatitis B, Chronic(3) Hepatitis B(3) Depressive Disorder, Major(2) Depressive Disorder(2) Neoplasms(2) (skip...) Phase 1:Abnormal: Colorectal Neoplasms(1) Kidney Failure, Chronic(1) Phase 1:Aborted: Pancreatic Neoplasms(1) Leukemia, Myeloid, Acute(1) Leukemia, Myeloid(1) Leukemia(1) Phase 2:Ongoing: Carcinoma, Non-Small-Cell Lung(4) Spondylarthritis(2) Spondylitis(2) Arthritis, Gouty(2) Lung Diseases(2) Sarcoma(2) Pulmonary Fibrosis(2) Retinal Vein Occlusion(2) Dermatitis(1) Dermatitis, Atopic(1) Arthritis(1) (skip...) Phase 2:Finished: Dermatitis(2) Dermatitis, Atopic(2) Hepatitis C(2) Infections(2) Non-alcoholic Fatty Liver Disease(1) Fatty Liver(1) Hepatitis C, Chronic(1) Esophageal Squamous Cell Carcinoma(1) Carcinoma, Squamous Cell(1) Carcinoma(1) Hepatitis, Chronic(1) (skip...) Phase 2:Abnormal: Hepatitis(1) Hepatitis B, Chronic(1) Hepatitis B(1) Hepatitis A(1) Phase 2:Aborted: Carcinoma, Renal Cell(1) Phase 3:Ongoing: Psoriasis(2) Acne Vulgaris(1) Asthma(1) Dermatitis(1) Dermatitis, Atopic(1) Arthritis, Gouty(1) (1) Diabetes Mellitus(1) Leukemia, Myeloid, Acute(1) Leukemia(1) Retinal Vein Occlusion(1) (skip...) Phase 3:Finished: Spondylitis, Ankylosing(1) Spondylitis(1) Hepatitis C(1) Infections(1) Anemia(1) Phase 4:Ongoing: Fibrosis(1) Bronchiectasis(1) Cystic Fibrosis(1) Burkholderia Infections(1) HIV Infections(1) Phase 4:Finished: Purpura, Thrombocytopenic, Idiopathic(1) Thrombocytopenia(1) Phase 4:Aborted: Anemia(1) Phase Not Applicable:Finished: Genetic Diseases, X-Linked(1) Parkinsonian Disorders(1) Dystonic Disorders(1) Dystonia(1) |
ALL | 29 | 24 | 14 | 2 | - | - | - | 31 |
| 2024 | 2 ⬤ | 6 ⬤ | 3 ⬤ | - | - | - | - | - | |||
| 2023 | 1 | 2 | 3 | 1 | - | - | - | 1 | |||
| 2022 | 3 | 4 | 5 | 1 | - | - | - | 3 | |||
|
ARGX
(argenx SE) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Syndrome(1) Myasthenic Syndromes, Congenital(1) Lambert-Eaton Myasthenic Syndrome(1) Renal Insufficiency(1) Phase 1:Finished: Nasopharyngeal Carcinoma(1) Phase 2:Ongoing: Syndrome(2) Neuritis(2) Sclerosis(1) Amyotrophic Lateral Sclerosis(1) Motor Neuron Disease(1) Myositis(1) Dermatomyositis(1) Sjogren\'s Syndrome(1) Tachycardia(1) Postural Orthostatic Tachycardia Syndrome(1) Delayed Graft Function(1) (skip...) Phase 2:Finished: Syndrome(2) Sjogren\'s Syndrome(1) Tachycardia(1) Postural Orthostatic Tachycardia Syndrome(1) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating(1) Polyneuropathies(1) Pemphigus(1) Purpura, Thrombocytopenic, Idiopathic(1) Thrombocytopenia(1) Myasthenia Gravis(1) Paresis(1) (skip...) Phase 3:Ongoing: Muscle Weakness(6) Myasthenia Gravis(6) Thyroid Diseases(2) Graves Ophthalmopathy(2) Eye Diseases(2) Polymyositis(2) Myositis(2) Dermatomyositis(2) Muscular Diseases(2) Pemphigoid, Bullous(2) Purpura, Thrombocytopenic, Idiopathic(2) (skip...) Phase 3:Finished: Muscle Weakness(3) Myasthenia Gravis(3) Purpura, Thrombocytopenic, Idiopathic(2) Thrombocytopenia(2) Paresis(2) Pemphigus(1) Phase 3:Aborted: Pemphigus(1) Purpura, Thrombocytopenic, Idiopathic(1) Thrombocytopenia(1) |
ALL | 3 | 10 | 14 | - | 1 | - | - | 1 |
| 2024 | 1 ⬤ | 2 ⬤ | 4 ⬤ | - | - | - | - | - | |||
| 2023 | 1 | 4 ⬤ | 1 ⬤ | - | - | - | - | 1 | |||
| 2022 | 1 | 2 | 4 ⬤ | - | - | - | - | - | |||
|
IONS
(Ionis Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Pelizaeus-Merzbacher Disease(1) Neoplasms, Plasma Cell(1) Multiple Myeloma(1) Atrophy(1) Shy-Drager Syndrome(1) Multiple System Atrophy(1) Phase 1:Finished: Diabetes Mellitus, Type 2(3) Hypertriglyceridemia(2) Neoplasms(1) Fibrosis(1) Cystic Fibrosis(1) Thalassemia(1) Cardiovascular Abnormalities(1) Hypercholesterolemia(1) Hyperlipoproteinemia Type II(1) Sclerosis(1) Amyotrophic Lateral Sclerosis(1) (skip...) Phase 2:Ongoing: Syndrome(2) Rett Syndrome(1) Prion Diseases(1) Polycythemia(1) Polycythemia Vera(1) Angelman Syndrome(1) Angioedemas, Hereditary(1) Angioedema(1) Atrophy(1) Geographic Atrophy(1) Macular Degeneration(1) (skip...) Phase 2:Finished: Diabetes Mellitus, Type 2(8) Diabetes Mellitus(7) Hypertension(4) Acromegaly(3) Kidney Diseases(3) Fatty Liver(2) Kidney Failure, Chronic(2) Hypertriglyceridemia(2) (2) Colitis, Ulcerative(2) Colitis(2) (skip...) Phase 2:Aborted: Diabetes Mellitus, Type 2(3) Diabetes Mellitus(3) Acute Disease(1) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases, Obstructive(1) Lung Diseases(1) Bronchitis, Chronic(1) Bronchitis(1) beta-Thalassemia(1) Thalassemia(1) Atrophy(1) (skip...) Phase 3:Ongoing: Hypertriglyceridemia(4) Amyloidosis(3) Syndrome(2) Hyperlipoproteinemia Type I(2) Cardiomyopathies(2) Atherosclerosis(1) Cardiovascular Diseases(1) Angioedemas, Hereditary(1) Angioedema(1) Amyloid Neuropathies(1) Polyneuropathies(1) (skip...) Phase 3:Finished: Amyloidosis(3) Amyloid Neuropathies(3) Polyneuropathies(3) Syndrome(2) Hyperlipoproteinemia Type I(2) Amyloid Neuropathies, Familial(2) Crohn Disease(2) Angioedemas, Hereditary(1) Angioedema(1) Hypertriglyceridemia(1) Carcinoma, Non-Small-Cell Lung(1) (skip...) Phase Not Applicable:Finished: Retinitis(2) Cytomegalovirus Retinitis(2) |
ALL | 3 | 6 | 12 | - | - | - | - | - |
| 2024 | - | 1 ⬤ | - | - | - | - | - | - | |||
| 2023 | 1 ⬤ | 1 | - | - | - | - | - | - | |||
| 2022 | - | - | 5 ⬤ | - | - | - | - | - | |||
|
RARE
(Ultragenyx Pharmaceutical Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Finished:
Distal Myopathies(1) Muscular Diseases(1) Phase 2:Ongoing: Hepatolenticular Degeneration(1) Syndrome(1) Angelman Syndrome(1) Phase 2:Finished: Syndrome(2) Mucopolysaccharidoses(2) Distal Myopathies(2) Muscular Diseases(2) Osteogenesis Imperfecta(2) Glycogen Storage Disease(1) Mucopolysaccharidosis VII(1) Carbohydrate Metabolism, Inborn Errors(1) Disease(1) Hypophosphatasia(1) Bone Diseases, Metabolic(1) (skip...) Phase 2:Aborted: Osteogenesis Imperfecta(2) Disease(1) Glycogen Storage Disease Type III(1) Glycogen Storage Disease(1) Mucopolysaccharidosis III(1) Mucopolysaccharidoses(1) Distal Myopathies(1) Muscular Diseases(1) Hemophilia B(1) Hemophilia A(1) Syndrome(1) (skip...) Phase 3:Ongoing: Osteogenesis Imperfecta(2) Mucopolysaccharidosis III(2) Mucopolysaccharidoses(2) Syndrome(1) Angelman Syndrome(1) Ornithine Carbamoyltransferase Deficiency Disease(1) Disease(1) Metabolic Diseases(1) Glycogen Storage Disease Type I(1) Glycogen Storage Disease(1) Phase 3:Finished: Mucopolysaccharidosis VII(2) Mucopolysaccharidoses(2) Syndrome(1) Distal Myopathies(1) Muscular Diseases(1) Phase 3:Aborted: Syndrome(1) Carbohydrate Metabolism, Inborn Errors(1) Movement Disorders(1) Distal Myopathies(1) Muscular Diseases(1) |
ALL | - | 2 | 8 | - | 2 | - | - | - |
| 2024 | - | - | 1 ⬤ | - | - | - | - | - | |||
| 2023 | - | - | 2 ⬤ | - | - | - | - | - | |||
| 2022 | - | - | 1 ⬤ | - | - | - | - | - | |||
|
ITCI
(Intra-Cellular Therapies Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Finished:
Schizophrenia(2) Psychotic Disorders(1) Phase 2:Ongoing: Parkinson Disease(1) Phase 2:Finished: Schizophrenia(2) Heart Failure, Systolic(1) Heart Failure(1) Parkinson Disease(1) Dementia(1) Alzheimer Disease(1) Phase 3:Ongoing: Bipolar Disorder(4) Depression(4) Depressive Disorder(4) Depressive Disorder, Major(3) Schizophrenia(2) Recurrence(1) Phase 3:Finished: Depressive Disorder(5) Depression(5) Bipolar Disorder(4) Depressive Disorder, Major(2) Schizophrenia(2) Disease(1) Phase 3:Aborted: Psychomotor Agitation(1) Dementia(1) Alzheimer Disease(1) |
ALL | 3 | 1 | 8 | - | 1 | - | - | - |
| 2024 | 1 ⬤ | - | 4 ⬤ | - | - | - | - | - | |||
| 2023 | 1 | 1 | 1 | - | - | - | - | - | |||
| 2022 | 1 | - | - | - | - | - | - | - | |||
|
ACAD
(ACADIA Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 2:Finished:
Schizophrenia(3) Mental Disorders(3) Psychotic Disorders(3) Parkinson Disease(3) Depression(2) Depressive Disorder(2) Alzheimer Disease(2) Pain, Postoperative(1) Aggression(1) Psychomotor Agitation(1) Depressive Disorder, Major(1) (skip...) Phase 2:Aborted: Osteoarthritis, Knee(1) Osteoarthritis(1) Parkinson Disease(1) Aggression(1) Psychomotor Agitation(1) Alzheimer Disease(1) Phase 3:Ongoing: Hyperphagia(2) Syndrome(2) Prader-Willi Syndrome(2) Mental Disorders(2) Psychotic Disorders(2) Alzheimer Disease(2) Child Development Disorders, Pervasive(2) Autism Spectrum Disorder(2) Autistic Disorder(2) Schizophrenia(2) Phase 3:Finished: Mental Disorders(5) Psychotic Disorders(5) Syndrome(4) Rett Syndrome(4) Parkinson Disease(4) Depressive Disorder, Major(2) Depression(2) Depressive Disorder(2) Neurodegenerative Diseases(2) Dementia(1) Schizophrenia(1) (skip...) Phase 3:Aborted: Depressive Disorder, Major(1) Depression(1) Depressive Disorder(1) Phase 4:Finished: Mental Disorders(1) Psychotic Disorders(1) Parkinson Disease(1) |
ALL | - | - | 8 | - | 2 | - | 1 | - |
| 2024 | - | - | 1 ⬤ | - | - | - | - | - | |||
| 2023 | - | - | 3 ⬤ | - | 1 | - | - | - | |||
| 2022 | - | - | 2 ⬤ | - | - | - | - | - | |||
|
AXSM
(Axsome Therapeutics Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Finished:
Sleepiness(1) Disorders of Excessive Somnolence(1) Narcolepsy(1) Sleep Apnea, Obstructive(1) Phase 2:Ongoing: Depressive Disorder, Treatment-Resistant(1) Depressive Disorder, Major(1) Depressive Disorder(1) Depression(1) Phase 2:Finished: Depressive Disorder, Major(3) Depression(3) Depressive Disorder(3) Depressive Disorder, Treatment-Resistant(2) Sleepiness(1) Cataplexy(1) Narcolepsy(1) Phase 3:Ongoing: Psychomotor Agitation(2) Alzheimer Disease(2) Binge-Eating Disorder(1) Feeding and Eating Disorders(1) Bulimia(1) Depressive Disorder, Major(1) Depression(1) Depressive Disorder(1) Dementia(1) Migraine Disorders(1) Sleepiness(1) (skip...) Phase 3:Finished: Migraine Disorders(3) Depressive Disorder, Major(3) Depression(3) Depressive Disorder(3) Psychomotor Agitation(2) Dementia(2) Alzheimer Disease(2) Disease(2) Sleepiness(1) Cataplexy(1) Disorders of Excessive Somnolence(1) (skip...) Phase 3:Abnormal: Syndrome(1) Reflex Sympathetic Dystrophy(1) Complex Regional Pain Syndromes(1) Phase 4:Ongoing: Depressive Disorder, Major(1) Depression(1) Depressive Disorder(1) Recurrence(1) Phase 4:Finished: Sleepiness(1) Disorders of Excessive Somnolence(1) Sleep Apnea, Obstructive(1) Sleep Apnea Syndromes(1) (1) |
ALL | - | 1 | 8 | 1 | 1 | - | 1 | - |
| 2024 | - | - | 2 ⬤ | 1 ⬤ | - | - | - | - | |||
| 2023 | - | - | 1 | - | - | - | - | - | |||
| 2022 | - | - | 2 | - | - | - | 1 | - | |||
|
EXEL
(Exelixis Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Neoplasms(2) Breast Neoplasms(2) Carcinoma, Renal Cell(2) Carcinoma(2) Squamous Cell Carcinoma of Head and Neck(1) Carcinoma, Ovarian Epithelial(1) Triple Negative Breast Neoplasms(1) Endometrial Neoplasms(1) Phase 1:Finished: Thyroid Neoplasms(3) Thyroid Cancer, Papillary(2) Renal Insufficiency(1) Liver Diseases(1) Thyroid Diseases(1) Adenocarcinoma, Follicular(1) Carcinoma, Renal Cell(1) Gliosarcoma(1) Glioblastoma(1) Neoplasms(1) Phase 1:Abnormal: Neoplasms(1) Phase 1:Aborted: Neoplasms(3) Polycythemia(2) Polycythemia Vera(2) Leukemia, Lymphocytic, Chronic, B-Cell(2) Leukemia, Lymphoid(2) Leukemia(2) Lymphoma, Large B-Cell, Diffuse(1) Lymphoma, Mantle-Cell(1) Lymphoma, Non-Hodgkin(1) Lymphoma(1) Carcinoma, Ovarian Epithelial(1) (skip...) Phase 2:Ongoing: Carcinoma, Renal Cell(2) Carcinoma(2) Triple Negative Breast Neoplasms(1) Endometrial Neoplasms(1) Phase 2:Finished: Glioblastoma(2) Astrocytoma(1) Carcinoma, Non-Small-Cell Lung(1) Lung Neoplasms(1) Digestive System Neoplasms(1) Gastrointestinal Neoplasms(1) Gastrointestinal Stromal Tumors(1) Phase 2:Aborted: Prostatic Neoplasms(1) Phase 3:Ongoing: Carcinoma(4) Carcinoma, Renal Cell(2) Squamous Cell Carcinoma of Head and Neck(1) Carcinoma, Squamous Cell(1) Colorectal Neoplasms(1) Prostatic Neoplasms(1) Carcinoma, Hepatocellular(1) Thyroid Diseases(1) Thyroid Neoplasms(1) Phase 3:Finished: Carcinoma(2) Carcinoma, Hepatocellular(1) Carcinoma, Renal Cell(1) Prostatic Neoplasms(1) Thyroid Diseases(1) Thyroid Neoplasms(1) Phase 3:Aborted: Prostatic Neoplasms(1) Phase 4:Ongoing: Thyroid Diseases(1) Carcinoma, Neuroendocrine(1) Thyroid Neoplasms(1) |
ALL | 4 | 2 | 7 | 1 | 1 | - | 1 | - |
| 2024 | - | - | - | - | - | - | - | - | |||
| 2023 | 1 ⬤ | 1 | 1 ⬤ | - | - | - | - | - | |||
| 2022 | - | - | 2 | - | - | - | - | - | |||
|
NRC
(National Research Corporation) commercial physical/biological research or service Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
COVID-19(1) Phase 1:Finished: COVID-19(1) Phase 2:Ongoing: Lymphoma(2) Hodgkin Disease(1) Leukemia, Myelogenous, Chronic, BCR-ABL Positive(1) Leukemia, Myeloid(1) Leukemia(1) Respiratory Distress Syndrome, Newborn(1) Respiratory Distress Syndrome, Adult(1) Coronavirus Infections(1) COVID-19(1) Communicable Diseases(1) Infections(1) (skip...) Phase 2:Finished: COVID-19(1) Overweight(1) Colorectal Neoplasms(1) Cardiovascular Diseases(1) Phase 2:Abnormal: Vomiting(2) Nausea(2) Recurrence(1) Graft vs Host Disease(1) (1) Anemia, Aplastic(1) Neutropenia(1) Shock, Septic(1) Postoperative Nausea and Vomiting(1) Phase 3:Ongoing: Lymphoma(3) Recurrence(1) Leukemia, Myeloid, Acute(1) Leukemia, Myeloid(1) Leukemia(1) Constriction, Pathologic(1) Malocclusion(1) Graft vs Host Disease(1) Hematologic Neoplasms(1) Lymphoma, Large B-Cell, Diffuse(1) Lymphoma, Follicular(1) (skip...) Phase 3:Finished: COVID-19(1) Postoperative Nausea and Vomiting(1) Vomiting(1) Nausea(1) Schizophrenia(1) Phase 3:Abnormal: Multiple Myeloma(1) Phase 4:Finished: Constriction, Pathologic(1) Tracheal Stenosis(1) Phase 4:Abnormal: Leukemia, Myeloid, Acute(1) Leukemia, Myeloid(1) Leukemia(1) Phase Not Applicable:Ongoing: Precursor Cell Lymphoblastic Leukemia-Lymphoma(3) Ischemia(2) Myocardial Ischemia(2) Cardiovascular Diseases(2) Atrial Fibrillation(2) Leukemia, Lymphoid(2) Leukemia(2) Dental Caries(1) Glucose Intolerance(1) Prediabetic State(1) Overweight(1) (skip...) Phase Not Applicable:Finished: Musculoskeletal Diseases(10) Dental Caries(3) Metabolic Syndrome(3) Syndrome(3) Anemia, Iron-Deficiency(3) Anemia(3) Musculoskeletal Pain(3) Diabetes Mellitus, Type 2(2) Diabetes Mellitus(2) Cardiovascular Diseases(2) Shoulder Pain(2) (skip...) Phase Not Applicable:Aborted: Wounds and Injuries(1) Female Athlete Triad Syndrome(1) Musculoskeletal Diseases(1) |
ALL | 1 | 5 | 7 | - | - | - | - | - |
| 2024 | - | 1 | 1 ⬤ | - | - | - | - | - | |||
| 2023 | - | - | 1 | - | - | - | - | - | |||
| 2022 | - | 2 | 1 | - | - | - | - | - | |||
|
VNDA
(Vanda Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Hematologic Neoplasms(1) Neoplasms(1) Phase 1:Finished: Schizophrenia(2) Autism Spectrum Disorder(1) Smith-Magenis Syndrome(1) Sleep Disorders, Circadian Rhythm(1) Sleep Wake Disorders(1) Pruritus(1) Renal Insufficiency(1) Liver Diseases(1) Phase 2:Ongoing: Keratoconjunctivitis Sicca(1) Dry Eye Syndromes(1) Phase 2:Finished: Pruritus(2) Eczema(2) Dermatitis(2) Dermatitis, Atopic(2) Anxiety Disorders(1) Conjunctivitis, Allergic(1) Conjunctivitis(1) Motion Sickness(1) Jet Lag Syndrome(1) Sleep Disorders, Circadian Rhythm(1) Sleep Wake Disorders(1) (skip...) Phase 2:Abnormal: Gastroparesis(1) Phase 2:Aborted: Mental Disorders(1) Psychotic Disorders(1) Parkinson Disease(1) Phase 3:Ongoing: Sleep Wake Disorders(3) Motion Sickness(2) Sleep Disorders, Circadian Rhythm(2) Autism Spectrum Disorder(1) Autistic Disorder(1) Nervous System Diseases(1) Dyssomnias(1) Parasomnias(1) Chronobiology Disorders(1) Severe Acute Respiratory Syndrome(1) Coronavirus Infections(1) (skip...) Phase 3:Finished: Disease(4) Sleep Disorders, Circadian Rhythm(3) Sleep Wake Disorders(3) Sleep Initiation and Maintenance Disorders(3) Schizophrenia(2) Motion Sickness(1) Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Jet Lag Syndrome(1) Syndrome(1) (skip...) Phase 3:Aborted: Eczema(1) Dermatitis(1) Dermatitis, Atopic(1) Phase 4:Ongoing: Schizophrenia(1) Phase 4:Finished: Sleep Disorders, Circadian Rhythm(1) Sleep Wake Disorders(1) |
ALL | 1 | 1 | 7 | 1 | 2 | - | 1 | - |
| 2024 | - | 1 | - | - | - | - | - | - | |||
| 2023 | - | - | 2 | - | - | - | - | - | |||
| 2022 | - | - | - | 1 | - | - | - | - | |||
|
NBIX
(Neurocrine Biosciences Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
Phase 1:Ongoing:
Parkinson Disease(1) Phase 1:Finished: Parkinson Disease(3) Central Nervous System Diseases(1) Brain Diseases(1) Neurodegenerative Diseases(1) Movement Disorders(1) Nervous System Diseases(1) Schizophrenia(1) Depressive Disorder(1) Syndrome(1) Tourette Syndrome(1) Liver Failure(1) (skip...) Phase 1:Aborted: Schizophrenia(1) Cerebellar Ataxia(1) Ataxia(1) Hyperplasia(1) Adrenocortical Hyperfunction(1) Adrenogenital Syndrome(1) Adrenal Hyperplasia, Congenital(1) Phase 2:Ongoing: Epilepsy(3) Brain Diseases(3) Schizophrenia(2) Syndrome(2) Depressive Disorder, Major(1) Depression(1) Depressive Disorder(1) Cognitive Dysfunction(1) Phase 2:Finished: Syndrome(5) Tourette Syndrome(5) Schizophrenia(5) Tardive Dyskinesia(4) Dyskinesias(4) Depressive Disorder, Major(2) Depression(2) Depressive Disorder(2) Epilepsy(2) Hyperplasia(2) Adrenocortical Hyperfunction(2) (skip...) Phase 2:Aborted: Syndrome(2) Tourette Syndrome(2) Seizures(1) Epilepsy(1) Phase 3:Ongoing: Hyperplasia(2) Adrenocortical Hyperfunction(2) Adrenogenital Syndrome(2) Adrenal Hyperplasia, Congenital(2) Chorea(2) Huntington Disease(2) Dyskinesias(1) Cerebral Palsy(1) Paralysis(1) Schizophrenia(1) Phase 3:Finished: Tardive Dyskinesia(3) Dyskinesias(3) Chorea(1) Huntington Disease(1) Phase 3:Aborted: Sleep Initiation and Maintenance Disorders(2) Schizophrenia(1) Depressive Disorder(1) Depression(1) Phase 4:Ongoing: Bipolar Disorder(1) Depressive Disorder, Major(1) Depressive Disorder(1) Schizophrenia(1) Tardive Dyskinesia(1) Dyskinesias(1) Phase 4:Finished: Tardive Dyskinesia(2) Dyskinesias(2) Substance Withdrawal Syndrome(1) |
ALL | 1 | 6 | 6 | 1 | 2 | - | - | - |
| 2024 | - | 1 ⬤ | 1 ⬤ | - | - | - | - | - | |||
| 2023 | - | - | - | 1 | - | - | - | - | |||
| 2022 | - | 3 ⬤ | 1 | - | - | - | - | - | |||
|
UTHR
(United Therapeutics Corporation) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Finished:
Hypertension(7) Hypertension, Pulmonary(2) Familial Primary Pulmonary Hypertension(1) Pulmonary Arterial Hypertension(1) Renal Insufficiency(1) Sclerosis(1) Scleroderma, Diffuse(1) Scleroderma, Systemic(1) Phase 1:Aborted: Bronchopulmonary Dysplasia(1) Hypertension(1) Familial Primary Pulmonary Hypertension(1) Phase 2:Finished: Hypertension(5) Familial Primary Pulmonary Hypertension(4) Pulmonary Arterial Hypertension(2) Neuroblastoma(1) Hypertension, Pulmonary(1) Scleroderma, Localized(1) Scleroderma, Diffuse(1) Scleroderma, Systemic(1) Phase 2:Abnormal: Hepatitis(1) Hepatitis C(1) Hepatitis A(1) Phase 2:Aborted: Hypertension(4) Hypertension, Pulmonary(3) Familial Primary Pulmonary Hypertension(1) Pulmonary Disease, Chronic Obstructive(1) Lung Diseases, Obstructive(1) Lung Diseases(1) Fibrosis(1) Pulmonary Fibrosis(1) Persistent Fetal Circulation Syndrome(1) Neuroblastoma(1) Sclerosis(1) (skip...) Phase 3:Ongoing: Lung Diseases(6) Fibrosis(4) Lung Diseases, Interstitial(4) Pulmonary Fibrosis(4) Idiopathic Pulmonary Fibrosis(3) Hypertension(2) Familial Primary Pulmonary Hypertension(2) Respiratory Tract Diseases(2) Pulmonary Arterial Hypertension(2) Hypertension, Pulmonary(2) Phase 3:Finished: Hypertension(9) Hypertension, Pulmonary(6) Pulmonary Arterial Hypertension(4) Familial Primary Pulmonary Hypertension(4) Small Cell Lung Carcinoma(1) Lung Neoplasms(1) Emphysema(1) Lung Diseases, Interstitial(1) Pulmonary Fibrosis(1) Lung Diseases(1) Phase 3:Aborted: Hypertension(11) Hypertension, Pulmonary(8) Lung Diseases(4) Familial Primary Pulmonary Hypertension(4) Pulmonary Disease, Chronic Obstructive(2) Lung Diseases, Obstructive(2) Ischemia(2) Peripheral Arterial Disease(2) Peripheral Vascular Diseases(2) Vascular Diseases(2) Respiratory Tract Diseases(1) (skip...) Phase 4:Ongoing: Ventricular Remodeling(1) Hypertension(1) Familial Primary Pulmonary Hypertension(1) Pulmonary Arterial Hypertension(1) Phase 4:Finished: Hypertension(6) Familial Primary Pulmonary Hypertension(5) Pulmonary Arterial Hypertension(2) Hypertension, Pulmonary(2) Phase 4:Aborted: Hypertension(6) Familial Primary Pulmonary Hypertension(4) Hypertension, Pulmonary(2) Pulmonary Arterial Hypertension(2) |
ALL | - | - | 6 | 1 | 2 | - | 2 | 2 |
| 2024 | - | - | - | - | - | - | - | - | |||
| 2023 | - | - | 1 ⬤ | - | - | - | - | - | |||
| 2022 | - | - | 1 ⬤ | 1 ⬤ | - | - | - | 1 | |||
|
PTCT
(PTC Therapeutics Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
Phase 1:Finished:
Muscular Dystrophy, Duchenne(2) Muscular Dystrophies(2) Leiomyosarcoma(1) Renal Insufficiency(1) Liver Diseases(1) Breast Neoplasms(1) Phase 1:Aborted: Leukemia, Myeloid, Acute(1) Leukemia, Myeloid(1) Leukemia(1) Neoplasms(1) Phase 2:Ongoing: Huntington Disease(2) Friedreich Ataxia(1) Cerebellar Ataxia(1) Ataxia(1) Sclerosis(1) Amyotrophic Lateral Sclerosis(1) Motor Neuron Disease(1) Phase 2:Finished: Muscular Dystrophy, Duchenne(6) Muscular Dystrophies(6) Fibrosis(4) Cystic Fibrosis(4) Syndrome(2) Leigh Disease(2) Gastroparesis(1) Phenylketonurias(1) Aniridia(1) Sclerosis(1) Amyotrophic Lateral Sclerosis(1) (skip...) Phase 2:Aborted: Muscular Dystrophy, Duchenne(3) Muscular Dystrophies(3) Aniridia(1) Amino Acid Metabolism, Inborn Errors(1) Metabolism, Inborn Errors(1) Hemophilia B(1) Hemophilia A(1) Neurofibromatosis 2(1) Neurofibroma(1) Neurofibromatosis 1(1) Neurofibromatoses(1) (skip...) Phase 3:Ongoing: Phenylketonurias(2) Friedreich Ataxia(1) Cerebellar Ataxia(1) Ataxia(1) Leiomyosarcoma(1) Mitochondrial Diseases(1) Muscular Dystrophy, Duchenne(1) Muscular Dystrophies(1) Phase 3:Finished: Muscular Dystrophy, Duchenne(3) Muscular Dystrophies(3) Fibrosis(3) Cystic Fibrosis(3) Nervous System Diseases(2) Muscular Disorders, Atrophic(2) Muscular Diseases(2) Musculoskeletal Diseases(2) Phenylketonurias(1) Friedreich Ataxia(1) Cerebellar Ataxia(1) (skip...) Phase 3:Aborted: Muscular Dystrophies(3) Fibrosis(2) Cystic Fibrosis(2) Muscular Dystrophy, Duchenne(2) Coronavirus Infections(1) COVID-19(1) Muscular Dystrophies, Limb-Girdle(1) Nervous System Diseases(1) Muscular Disorders, Atrophic(1) Muscular Diseases(1) Musculoskeletal Diseases(1) (skip...) |
ALL | - | 5 | 6 | - | 2 | - | - | - |
| 2024 | - | 1 ⬤ | 1 ⬤ | - | - | - | - | - | |||
| 2023 | - | - | - | - | - | - | - | - | |||
| 2022 | - | 3 ⬤ | 3 ⬤ | - | - | - | - | - |
(Continued) Drugs Marketing/Approval Status in USA, Europe, Canada
| Symbol | SMA (50w/20w/10w/5w / 50d/20d/10d/5d) | Year | United States | Europe | Canada | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human | Animal | Bioproduct | Human | Animal | Human | Animal | ||||||||||
| Marketed | Tentative Approval | Marketed | Tentative Approval | Marketed | Tentative Approval | Marketed | Positive | Marketed | Positive | Marketed | Approved | Marketed | Approved | |||
|
AZN
(AstraZeneca PLC) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 43 | - | - | - | - | - | 32 | 1 | - | - | 44 | 3 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | 1 | 1 ⬤ | - | - | ||
| 2023 | 4 | - | - | - | - | - | 1 | 1 | - | - | 3 | - | - | - | ||
| 2022 | 3 | - | - | - | - | - | 5 | - | - | - | 1 | - | - | - | ||
|
MRK
(Merck & Company Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 34 | 1 | - | - | 19 | - | 47 | 2 | - | - | 37 | 1 | - | - |
| 2024 | - | - | - | - | - ⬤ | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | 1 | 2 | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | 1 | - | - | - | 1 | 1 | - | - | ||
|
NVS
(Novartis AG) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 75 | - | - | - | 6 | - | 62 | 1 | - | - | 92 | 11 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | 3 ⬤ | - | - | ||
| 2023 | 3 | - | - | - | - | - | 1 | 1 | - | - | 2 | 1 | - | - | ||
| 2022 | 3 | - | - | - | - | - | 4 | - | - | - | 3 | - | - | - | ||
|
ABBV
(AbbVie Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 77 | - | - | - | - | - | 16 | - | - | - | 66 | 3 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | - | - | ||
| 2023 | - | - | - | - | - | - | 2 | - | - | - | 7 | - | - | - | ||
| 2022 | 1 | - | - | - | - | - | - | - | - | - | 9 | - | - | - | ||
|
LLY
(Lilly Eli & Company) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 41 | - | - | - | - | - | 29 | 1 | - | - | 38 | 4 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | 1 | 1 ⬤ | - | - | ||
| 2023 | 2 | - | - | - | - | - | 2 | 1 | - | - | 2 | - | - | - | ||
| 2022 | 1 | - | - | - | - | - | 2 | - | - | - | - | 2 | - | - | ||
|
PFE
(Pfizer Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 104 | 1 | - | - | 6 | - | 54 | 2 | - | - | 159 | 15 | - | - |
| 2024 | - | - | - | - | - ⬤ | - | - | - | - | - | 1 | - | - | - | ||
| 2023 | 6 | - | - | - | - | - | 2 | 2 | - | - | 4 | 1 | - | - | ||
| 2022 | 1 | - | - | - | - | - | 5 | - | - | - | 4 | - | - | - | ||
|
SNY
(Sanofi SA) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 42 | - | - | - | 21 | - | 48 | 1 | - | - | 96 | 11 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | 2 ⬤ | - | - | ||
| 2023 | - | - | - | - | - | - | - | 1 | - | - | 2 | 2 | - | - | ||
| 2022 | - | - | - | - | - | - | 5 | - | - | - | 4 | - | - | - | ||
|
BMY
(Bristol-Myers Squibb Company) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 28 | - | - | - | - | - | 25 | - | - | - | 29 | 1 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | 2 | - | - | - | 1 | - | - | - | ||
| 2022 | 4 | - | - | - | - | - | 2 | - | - | - | 2 | 1 | - | - | ||
|
NVO
(Novo Nordisk A S) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 23 | - | - | - | 4 | - | 22 | - | - | - | 28 | 5 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | - | - | - | - | 2 | 1 | - | - | ||
| 2022 | - | - | - | - | - | - | 1 | - | - | - | 2 | 1 | - | - | ||
|
AMGN
(Amgen Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 24 | - | - | - | - | - | 18 | - | - | - | 21 | 2 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 2 | - | - | - | - | - | 1 | - | - | - | 1 | - | - | - | ||
| 2022 | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | ||
|
TAK
(Takeda Pharmaceutical Company Limited) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 36 | - | - | - | 2 | - | 29 | 2 | - | - | 44 | 5 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 2 | - | - | - | - | - | - | 2 | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | 2 | - | - | - | 2 | - | - | - | ||
|
REGN
(Regeneron Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 8 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
GILD
(Gilead Sciences Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 29 | - | - | - | - | - | 22 | - | - | - | 21 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | 2 | - | - | - | - | - | 1 | - | - | - | 2 | - | - | - | ||
|
INCY
(Incyte Corp.) commercial physical/biological research or service Insider Trading Institutional Holding |
|
ALL | 4 | - | - | - | - | - | 4 | - | - | - | 2 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | 1 | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
BGNE
(BeiGene Ltd.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 1 | - | - | - | - | - | 1 | 1 | - | - | 1 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
VRTX
(Vertex Pharmaceuticals Incorporated) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 7 | - | - | - | 1 | - | 4 | 1 | - | - | 11 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | - | 1 | - | - | 2 | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | ||
|
BIIB
(Biogen Idec Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 10 | - | - | - | 1 | - | 7 | - | - | - | 5 | 2 | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
SBFM
(Sunshine Biopharma Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 18 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
ARGX
(argenx SE) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | 1 | - | - | - | 1 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | - | - | - | - | 1 | - | - | - | ||
| 2022 | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | ||
|
IONS
(Ionis Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
RARE
(Ultragenyx Pharmaceutical Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | - | - | - | - | 2 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
ITCI
(Intra-Cellular Therapies Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
ACAD
(ACADIA Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
AXSM
(Axsome Therapeutics Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | - | - | - | - | 1 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
EXEL
(Exelixis Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
NRC
(National Research Corporation) commercial physical/biological research or service Insider Trading Institutional Holding |
|
ALL | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
VNDA
(Vanda Pharmaceuticals Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 3 | - | - | - | - | - | 1 | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
NBIX
(Neurocrine Biosciences Inc.) biological products (diagnostic and non diagnostic) Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
UTHR
(United Therapeutics Corporation) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 5 | - | - | - | - | - | - | - | - | - | 2 | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
|
PTCT
(PTC Therapeutics Inc.) pharmaceuticals Insider Trading Institutional Holding |
|
ALL | 2 | - | - | - | - | - | 2 | - | - | - | - | - | - | - |
| 2024 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2022 | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - |